 
 
Budesonide  Versus Fluticason e for Treatment of Eosinophilic Esophagitis  
 
NCT number  02019758  
Document Date  14Mar2019  
 
 
CONFIDENTIAL  CLINICAL RESEARCH PROTOCOL   
 
 
BUDESONIDE VERSUS FL UTICASONE FOR TREATM ENT OF 
EOSINOPHILIC ESOPHAG ITIS  
 
Principal Investigator : Evan S Dellon, MD, MPH  
Associate Professor of Medicine  
University of North Carolina School of Medicine  
Chapel Hill, NC   
Co-Investigators : John A Baron, MD  
Professor of Medicine  
University of North Carolina School of Medicine  
Chapel Hill, NC  
 
Joseph A Galanko, PhD  
Research Assistant Professor of Medicine  
University of North Carolina School of Medicine  
Chapel Hill, NC  
 
Nicholas J Shaheen, MD, MPH  
Professor of Medicine and Epidemiology  
Director, Center of Esophageal Diseases and Swallowing  
University of North Carolina School of Medicine  
Chapel Hill,  NC 
 
John T Woosley, MD  
Professor of Pathology and Lab Medicine  
University of North Carolina School of Medicine  
Chapel Hill, NC  
 
Study Product:  Budesonide, Pulmicort  
Fluticasone, Flovent  
Funding Sponsor : National Institute of Diabetes and Digestive and Kidney 
Diseases ( NIDDK  – R01DK101856 ) 
IND Number:  105981  
Registration:  Clinicaltrials.gov – [STUDY_ID_REMOVED]  
IRB approval:  UNC IRB # 13 -4047  
 
Initial version:  June 21, 2016  
Version 2.0: March 16, 2017  
Version 3.0:  March 14, 2019   

Budesonide vs Fluticasone Protocol – TREET Trial   Page ii 
Version: March 14, 2019  
CONFIDENTIAL   
Changes from Previous Version  
 
This version includes the following changes to the previous version of the protocol, 
Version 2.0 (16Mar2017 ). 
 
Section s 3.2, 3.3, 3.4 , 7.1 Modified study endpoints to reference 
outcomes, and c larified primary, 
secondary, and exploratory outcomes.  
Entire document  Administrative changes to protocol 
version number and date  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page iii 
Version: March 14, 2019  
CONFIDENTIAL   
 
 
 
Table of Contents  
 
STUDY SUMMARY  ................................ ................................ ................................ ................................ ...... 1 
1   INTRODUCTION  ................................ ................................ ................................ ................................ ...... 3 
1.1 BACKGROUND  ................................ ................................ ................................ ................................  3 
1.2 INVESTIGATIONAL AGENTS  ................................ ................................ ................................ ..............  5 
1.3 PRECLINICAL DATA ................................ ................................ ................................ ........................  6 
1.4 CLINICAL DATA TO DATE................................ ................................ ................................ .................  7 
1.5 DOSE RATIONALE AND RISK/BENEFITS  ................................ ................................ ............................  9 
2 STUDY OBJECTIVES  ................................ ................................ ................................ .......................  10 
3 STUDY DESIGN  ................................ ................................ ................................ ................................ . 10 
3.1 GENERAL DESIGN  ................................ ................................ ................................ ........................  10 
3.2 AIM 1 STUDY OUTCOMES  ................................ ................................ ................................ .............  10 
3.3 AIM 2 STUDY OUTCOMES  ................................ ................................ ................................ .............  11 
3.4 AIM 3 STUDY OUTCOMES  ................................ ................................ ................................ .............  11 
4 SUBJECT SELECTION AN D WITHDRAWAL  ................................ ................................ ..................  12 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ....................  12 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ...................  12 
4.3 SUBJECT RECRUITMENT AND SCREENING  ................................ ................................ .....................  12 
4.4 EARLY WITHDRAWAL OF SUBJECTS ................................ ................................ ...............................  12 
4.4.1  When and How to Withdraw Subjects  ................................ ................................ ...................  12 
4.4.2  Lost to Follow -Up................................ ................................ ................................ ...................  13 
4.4.3  Data Collection and Follow -up for Withdrawn Subjects  ................................ ........................  13 
5 STUDY DRUGS  ................................ ................................ ................................ ................................ . 13 
5.1 DESCRIPTION  ................................ ................................ ................................ ...............................  13 
5.2 TREATMENT REGIMEN  ................................ ................................ ................................ ..................  13 
5.3 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS  ................................ .......................  13 
5.4 PREPARATION AND ADMINISTRATION OF STUDY DRUG ................................ ................................ ... 13 
5.5 SUBJECT COMPLIANCE MONITORING  ................................ ................................ .............................  14 
5.6 PRIOR AND CONCOMITANT THERAPY  ................................ ................................ .............................  14 
5.7 PACKAGING AND LABELING  ................................ ................................ ................................ ...........  14 
5.8 BLINDING OF STUDY DRUG ................................ ................................ ................................ .............  1 
5.9 RECEIVING , STORAGE , DISPENSING AND RETURN  ................................ ................................ ............  1 
5.9.1  Receipt of Drug Supplies  ................................ ................................ ................................ .........  1 
5.9.2  Storage  ................................ ................................ ................................ ................................ .... 1 
5.9.3  Dispensing of Study Drug  ................................ ................................ ................................ ........  1 
5.9.4  Return or Destruction of Study Drug  ................................ ................................ .......................  1 
6 STUDY PROCEDURES  ................................ ................................ ................................ .......................  2 
6.1 CASE IDENTIFICATION  ................................ ................................ ................................ .....................  2 
6.2 BASELINE VISIT (VISIT 1) ................................ ................................ ................................ ................  2 
6.2.1  Consenting Procedure  ................................ ................................ ................................ .............  3 
6.2.2  Biopsy Collection and Processing, Research Related  ................................ ............................  3 
6.2.3  Blood Sample Collection and Processing  ................................ ................................ ...............  4 
6.3 TREATMENT START (VISIT 2) ................................ ................................ ................................ ..........  5 
6.4 MID-TREATMENT (VISIT 3) ................................ ................................ ................................ ..............  5 
6.5 END OF TREATMENT (VISIT 4) ................................ ................................ ................................ .........  5 
Budesonide vs Fluticasone Protocol – TREET Trial   Page iv 
Version: March 14, 2019  
CONFIDENTIAL  6.6 FOLLOW -UP PHONE CALLS AND E MAILS  ................................ ................................ ............................  6 
6.7 STUDY END (VISIT 5) ................................ ................................ ................................ ......................  6 
7 STATISTICAL PLAN  ................................ ................................ ................................ ...........................  7 
7.1 SAMPLE SIZE DETERMINATION  ................................ ................................ ................................ ........  7 
7.2 STATISTICAL METHODS  ................................ ................................ ................................ ..................  7 
7.3 SUBJECT POPULATION (S) FOR ANALYSIS  ................................ ................................ .........................  8 
8 SAFETY AND ADVERSE E VENTS  ................................ ................................ ................................ ..... 8 
8.1 DEFINITIONS  ................................ ................................ ................................ ................................ .. 8 
8.2 RECORDING OF ADVERSE EVENTS  ................................ ................................ ................................  10 
8.3 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ................................ . 11 
8.3.1  Investigator reporting: notifying the study sponsor ................................ ................................  11 
8.3.2  Notifying the UNC IRB  ................................ ................................ ................................ ...........  11 
8.3.3  Notifying the FDA  ................................ ................................ ................................ ..................  12 
8.4 UNBLINDING PROCEDURES  ................................ ................................ ................................ ...........  13 
8.5 STOPPING RULES  ................................ ................................ ................................ .........................  13 
8.6 MEDICAL MONITORING  ................................ ................................ ................................ .................  13 
8.6.1  Independent Data and Safety Monitoring Board  ................................ ................................ ... 13 
9 DATA HANDLING AND RE CORD KEEPING  ................................ ................................ ...................  14 
9.1 CONFIDENTIALITY  ................................ ................................ ................................ .........................  14 
9.2 SOURCE DOCUMENTS  ................................ ................................ ................................ ..................  14 
9.3 CASE REPORT FORMS ................................ ................................ ................................ ..................  14 
9.4 RECORDS RETENTION  ................................ ................................ ................................ ..................  14 
10 STUDY MONITORING, AU DITING, AND INSPECTI NG ................................ ................................ .. 15 
10.1  STUDY MONITORING PLAN ................................ ................................ ................................ ............  15 
10.2  AUDITING AND INSPECTING  ................................ ................................ ................................ ...........  16 
11 ETHICAL CONSIDERATIO NS ................................ ................................ ................................ ..........  16 
12 STUDY FINANCES  ................................ ................................ ................................ ............................  16 
12.1  FUNDING SOURCE  ................................ ................................ ................................ ........................  16 
12.2  CONFLICT OF INTEREST  ................................ ................................ ................................ ................  16 
12.3  SUBJECT STIPENDS OR PAYMENTS  ................................ ................................ ...............................  16 
13 PUBLICATION PLAN  ................................ ................................ ................................ ........................  17 
14 REFERENCES  ................................ ................................ ................................ ................................ ... 18 
 
  
Budesonide vs Fluticasone Protocol – TREET Trial   Page vi 
Version: March 14, 2019  
CONFIDENTIAL  List of Abbreviations   
 
 
 
 
Item Definition  
AUC  Area Under the Curve  
CEDAS  Center for Esophageal Diseases and Swallowing  
EC Ethics Committee  
eCRF  Electronic Case Report Form  
EGD  Esophagogastroduodenoscopy  
EoE Eosinophilic Esophagitis  
EoG Eosinophilic  Gastroenteritis  
Eos Eosinophils  
EREFS Score  EoE Endoscopic Reference Score104 
FFPE  Formalin -fixed paraffin embedded  
H&E Hematoxylin & Eosin  
HPF High Power Field  
IDS Investigational Drug Service (at UNC)  
IRB Institutional Review Board  
MDI Multi -dose Inhaler  
NEB Nebulized and then Swallowed  
OVB  Oral Viscous Budesonide  
PPI Proton -Pump Inhibitor  
 
 
 
 
 
Budesonide vs Fluticasone Protocol – TREET Trial   page 1 
Version:  March 14, 2019  
CONFIDENTIAL  Study Summary  
Title Budesonide versus Fluticasone for Treatment of Eosinophilic Esophagitis   
Short Title  TREET trial ( TReatment of EoE with Topical steroids)  
Methodology  Prospective, randomized, double -blind, double -dummy, single center clinical trial 
comparing oral viscous budesonide (OVB) to fluticasone multi -dose inhaler (MDI) 
for treatment of eosinophilic esophagitis (EoE).  
Study Duration  3 years  
Study Center(s)  University of North Carolina, Chapel Hill, NC  
Objectives  Primary objective:  To determine whether viscous budesonide is more effective than 
fluticasone MDI for improving esophageal eosinophil counts and symptoms of 
dysphagia in patients with EoE after an initial treatment course.  
 
Secondary objective : To determine whethe r treatment with viscous budesonide 
results in less symptomatic and histologic recurrence than fluticasone MDI one year 
after the initial treatment course.   
Number of 
Subjects  200 
Diagnosis and 
Main Inclusion 
Criteria  Inclusion Criteria : 
1) Age 16 -80 years old 
2) New diagnosis of EoE as per consensus guidelines. Cases must have 
symptoms of dysphagia, persistent esophageal eosinophilia ( ≥ 15 
eosinophils in at least one high -power field) after 8 weeks of treatment with 
a twice daily proton -pump inhibitor, and oth er competing causes of 
esophageal eosinophilia excluded   
Exclusion Criteria : 
1) Medical instability that precludes safely performing upper endoscopy  
2) Ongoing or recent symptoms of intestinal bleeding (throwing up blood, 
passing blood in the stool)  
3) Concomitant eosinophilic gastroenteritis (EoG)  
4) Esophageal narrowing or stricturing that will not allow a standard 9 mm 
upper endoscopy scope to pass  
5) Cancer in the esophagus, stomach, or intestine  
6) Prior surgery on the esophagus (e.g., removal of part of the esophagus)  
7) Esophageal varices (dilated blood vessels in the esophagus)  
8) Current use of blood thinners like Plavix or Coumadin that are not stopped 
prior to endoscopy procedures  
9) Corticosteroid exposure within the four weeks prior to the baseline 
endoscopy .  Exclusionar y corticosteroid exposure is defined as any 
swallowed topical steroids for EoE or systemic steroids for any condition 
within the four weeks prior to the baseline endoscopy.  Corticosteroids 
used for asthma or intranasal corticosteroids are not an exclusion  and are 
allowable.  
10) Pregnancy  
11) Inability to read or speak English  
Study Product, 
Dose, Route, 
Regimen  Oral Viscous Budesonide (OVB), 1 mg swallowed twice daily  
Fluticasone Multi -Dose Inhaler (MDI) , 4 puffs (880mcg ) swallowed  twice daily  
Duration of 
administration  8 weeks  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 2 
Version: March 14, 2019  
CONFIDENTIAL  Reference therapy  Reference therapies are a placebo viscous slurry  and a placebo MDI .  All patients 
will receive either active OVB/placebo MDI, or placebo slurry/active MDI, in double 
blind fashion.  
Statistical 
Methodology  To test whether OVB is more effective than fluticasone MDI for improving 
eosinophil counts, the mean post -treatment maximum eosinophil count will be 
compared between the OVB and MDI groups using a two -sample t -test. To test 
whether OVB results in less symp tomatic recurrence than fluticasone MDI,  
survival analysis will be performed with the interval between treatment end (week 
8) and recurrent symptoms  or study end (week 60) as the time of interest.  
Symptoms will be measured with the Dysphagia Symptom Questionnaire, a 
validated instrument in EoE.  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 3 
Version: March 14, 2019  
CONFIDENTIAL  1   Introduction  
This document is a protocol for a human research study. This study is to be conducted according to US 
and international standards of Good  Clinical Practice (FDA Title 21 part 312 and International Conference 
on Harmonization guidelines), applicable government regulations and Institutional research policies and 
procedures.  
1.1 Background  
Eosinophilic esophagitis is a previously rare condition w ith a rapidly increasing incidence  
Eosinophilic esophagitis (EoE) is an immune -mediated 
clinicopath ologic entity whereby abnormal infiltration of  
eosinophils into the esophageal mucosa leads to  
dysphagia, progressive esophageal stenosis, and food  
impaction.1-3 First described in 19784 and initially felt to  
be rare,5 estimates in multiple populations, including 
our center, show that incidence has increased more 
than four-fold in the last five to ten years  (Figure 1) .6-9 
Because EoE is chronic, the prevalence is also  
increasing.6, 7, 10, 11 Overall, between 5% and 16% of 
patients undergoing endoscopy for dysphagia will have 
EoE,12-15 and more than 50% of patients presenting to 
an emergency room with food impaction are now 
diagnosed with EoE.3, 16 Because of this dramatic 
change in epidemiology and the increasing burden of 
disease attributable to EoE, the NIDDK -sponsored 
National Commission on Digestive Diseases has made 
research in EoE a priority.17  
 
 
EoE is diagnosed by clinical and pathologic criteria  
While dysphagia is the clinical hallmark and most 
common  symptom of EoE in adolescents and 
adults,1, 18, 19 other  symp toms can include heartburn, 
reflux, and chest pain.2, 20, 21 When suggestive 
symptoms are present, upper endoscopy with  biopsy 
is required to make the diagnosis.2 Endoscopic 
signs of  EoE can include esophageal rings, 
strictures, luminal  narrowing, linear f urrows, white 
plaques or exudates, and a  loss of vascularity  
(Figure 2) .1, 18, 22, 23 On esophageal biopsy,  
demonstration of epithelial eosinophilia is required 
for diagnosis, and the current accepted threshold 
level is 15  eosinophils per high -power field (eos/hpf).2 Because the  symptoms and signs of EoE can be 
non-specific, diagnostic  criteria have been published and recently updated (Table 1).2 The guidelines 
require the presence of esophageal eosinophilia  in the correct clinical setting. They also requir e exclusion 
of other conditions that may cause esophageal eosinophilia  before a diagnosis of EoE can be formally 
confirmed.  
 
Table 1: Consensus diagnostic criteria for EoE2 
 Clinical symptoms of esophageal dysfunction  
 ≥ 15 eosinophils in at least one high-power field  
 Eosinophilia limited to the esophagus with other  
causes of esophageal eosinophilia excluded  
 
Figure 1:   Rapid increase in new cases of EoE at UNC in 
both adults and children.  This increase persists when 
normalized for endoscopy and biopsy volume , and mirrors 
national and international trends  
Figure 2:   Endoscopic views of (A) the normal 
esophagus and (B) EoE with rings and narrowing.  
Figure 1:   Rapid increase in new cases of EoE at UNC in 
both adults and children.  This increase persists when 
normalized for endoscopy and biopsy volume , and mirrors 
national and international trends  
Figure 2:   Endoscopic views of (A) the normal 
esophagus and (B) EoE with rings and narrowing.  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 4 
Version: March 14, 2019  
CONFIDENTIAL  The treatment approach to EoE is rudimentary, but corticosteroids are the mainstay of therapy for 
EoE 
Despite the fact that EoE has become a major cause of upper gastrointestinal morbidity in both children 
and adults, the approach to treatment of EoE is rudimentary and evidence to guide practice is sorely 
needed (Table 2). Because data suggest that a Th2 -mediated response to allergic pathogens governs 
esophageal eosinophil infiltration,24 corticosteroids are currently the first -line pharmaceutical treatment 
option for patients with EoE.2, 25 However, because no medications in this class have been specifically 
formulated for EoE, patients are pre scribed asthma preparations such as fluticasone in a multi -dose 
inhaler (MDI) or aqueous budesonide. Patients are asked to swallow, rather than inhale, these 
medications to coat the esophagus and provide a topical anti -inflammatory effect. For fluticasone MDI, 
patients puff the medication into their mouth during a breath hold and then swallow it.26, 27 For aqueous 
budesonide, patients mix the liquid into a slurry with a sugar substitute such as sucralose and then 
swallow it; this has been termed “oral visco us budesonide,”  or OVB.28, 29 Another technique is to swallow 
the aerosolized droplets of aqueous budesonide after it has been  nebulized.30 These approaches were 
first described in observational studies,28, 31 -37 and several small  randomized clinical trials have now 
shown that these treatment strategies can be effective for decreasing  levels of esophageal eosinophilia 
and improving symptoms related to EoE.26, 29, 30, 38, 39 However, the dose  ranges, length of treatments, 
method of drug delivery, assess ment of symptoms, and patient inclusion criteria  vary widely between 
these studies,25 so studies cannot be directly compared to draw conclusions about  efficacy.  
 
Table 2: Major unanswered questions regarding EoE treatment  
1) What topical corticosteroid agent  is the most effective?  
Importance : Doctors do not know what medication to use first.  
2) After an initial treatment course, what is the durability of 
response?  
Importance : Patients cannot be properly informed about 
treatment outcomes and symptom recurrence.  
3) Which patients are most likely to respond to topical 
corticosteroids?  
Importance : Patients who might not respond are subjected to 
unnecessary steroid exposure and provision of non -steroid 
therapies is delayed.  
 
The most effective topical steroid to use as a first line agent in EoE is unknown  
A major gap in the current knowledge regarding EoE treatment is that it is unknown which topical steroid 
is most effective. Because of this, practitioners do not know what medication to use first and cannot 
provide  accurate information to patients about treatment outcomes. In a study of patterns of practice 
related to EoE  performed by our group, the vast majority of gastroenterologists who prescribed a topical 
steroid chose  fluticasone MDI as their initial steroid ag ent.40 However, this choice is not supported by 
comparative  effectiveness data, and it is unknown whether a different medication such as OVB might be 
more effective.  This question has substantial practical implications. Topical steroids are not universally  
effective, with 13% to  50% of subjects failing to respond depending on the study and outcome measure.26, 
29, 30, 41 It is possible that  poor treatment responses are due to difficulties administering the medication or 
to sub -optimal formulations.  For examp le, fluticasone MDI is designed for pulmonary deposition and may 
be inefficiently delivered to the  esophagus, whereas the entire dose of OVB is delivered to the 
esophagus.42 Natural history data show that  prolonged symptom duration in EoE is associated wit h 
increased risk of esophageal strictures,43 so there is a  strong rationale to treat with the most effective 
agent available at the time of diagnosis. However, providers  need efficacy data to select the best 
medication to treat patients with EoE.  
 
The dura bility of the treatment response to topical steroid treatment for EoE is unknown  
Another major gap in knowledge is that the durability of treatment response in EoE is unknown. The few 
data available regarding durability of response are inconclusive. In a r etrospective trial of adults treated 
with an  initial two -week course of fluticasone MDI, 29 of 32 patients reported recurrent dysphagia at a 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 5 
Version: March 14, 2019  
CONFIDENTIAL  mean of 9  months.44 In a prospective trial, subjects who 
previously responded to a two -week course of nebulized the n 
swallowed budesonide were randomized to low dose 
budesonide or to placebo.45 After 50 weeks of treatment,  all 
14 patients in the placebo arm had recurrent esophageal 
eosinophilia, and the median time to symptom  relapse was 95 
days. However, in this study  the initial treatment course (2 
weeks) was shorter than the current  accepted standard of 8 
weeks, so the recurrence rates might have been higher. 
Providers need high quality  data from larger studies to 
accurately inform patients when recurrent symptoms an d 
esophageal eosinophilia  can be expected after an initial 
treatment course. A better understanding of durability of 
response will also  inform decisions regarding which patients 
with EoE might need long -term therapy.46 
 
Predictors of response to steroid therapy are unknown, 
but candidate tissue biomarkers can be identified from 
the postulated pathogenesis of EoE  
A third key issue in the treatment of EoE is th at predictors of 
response to topical steroid treatment have not been studied. 
Of the four published small randomized trials in EoE comparing topical steroids to placebo,26, 27, 29, 30 only 
one attempted to assess predictors.30 Of 10 clinical and histologic  factors examined in that study, none 
were predictive, but there were only 36 patients in the trial so the null result could be due to type II error. 
Identification of predictors of treatment response is important not only to target therapy to those most 
likely to respond, but to minimize unnecessary steroid exposure and institute effective non -steroid 
alternatives such as dietary elimination in those least likely to respond.2 Candidate biomarkers for 
prediction of treatment response can be selected based o n the pathophysiology  of EoE  (Figure 3) . The 
presence of eosinophils in the esophageal mucosa is abnormal,47,48 and both murine and human data 
suggest a Th2 -mediated response to allergen sensitization governs esophageal eosinophil infiltration and 
activati on.34, 49 -56 In particular, IL -13 stimulates esophageal epithelial cells to produce eotaxin -3, a potent 
chemokine which is increased 50 -fold in patients with EoE compared to controls.56-60 Once activated, 
eosinophils degranulate and release factors such as major basic protein (MBP), which can disrupt 
epithelium and is increased in patients with EoE.61-63 The Th2 response also results in mast cells 
infiltrating the esophagus, likely via IL -9.64 In addition to increased numbers of mast cells in patients with 
EoE, mast cell -associated genes are upregulated in EoE, and mast cells are an important mediator of the 
esophageal remodelling and fibrosis that causes esophageal strictures in EoE.54, 56,  57, 65 -69 In addition, 
patients who successfully respond to topical steroid therapy have resolution of esophageal eosinophilia 
(and therefore a decrease in MBP release), normalization of eotaxin -3 gene expression, and resolution of 
esophageal mastocytosis .26, 30, 60 While MBP, eotaxin 3, and mast cells are candidate markers of 
treatment response in EoE, they have yet to be studied for this application.  
1.2 Investigational Agent s 
Oral viscous budesonide  (OVB) is a swallowed, or topical , steroid slurry .  We will  formulate this to be  
equivalent  to what is used clinically: 1 mg/4 mL aqueous budesonide mixed with 10 g of sucralose.28, 29, 42  
Rather than  asking the subjects to mix the slurry on their own and risk inconsistent formulations, a 
weakness of prior  studie s, the UNC investigational drug service (IDS ) will provide pre -mixed OVB to all 
patients. For the purposes of compounding the medication to be dispensed as a one -month supply, the 
constituent elements of aqueous budesonide are combined in bulk with sucralo se to yield the necessary 
concentration and consistenc y.  The dose for OVB has been chosen because it is the most commonly 
studied dose, including our prior study, so we can accurately estimate response rates.28, 29, 39, 42  Subjects  
randomized to this arm will also be instructed to use a placebo inhaler identical to the fluticasone MDI, 
with instructions t o swallow 4 puffs twice daily.  
 
Figure 3 :  Proposed pathogenic pathway for EoE.  
Allergens or other yet to be determined etio logic factors, in 
the proper genetic milieu, stimulate a Th2 response leading 
to IL -13 production .  IL -13 stimulates the esophageal 
epithelial cells to produce eotaxin -3, which in turn acts as a 
chemoattractant and activates eosinophils. Eosinophils 
releas e MBP, a cytotoxic granule that can injure the 
epithelium.  The Th2 response also produces IL -9 which 
recruits mast cells.  Mast cells are involved in promoting 
fibrosis, which leads to esophageal strictures.  
Figure 3 :  Proposed pathogenic pathway for EoE.  
Allergens or other yet to be determined etiologic factors, in 
the proper genetic milieu, stim ulate a Th2 response leading 
to IL -13 production .  IL -13 stimulates the esophageal 
epithelial cells to produce eotaxin -3, which in turn acts as a 
chemoattractant and activates eosinophils. Eosinophils 
release MBP, a cytotoxic granule that can injure the 
epithelium.  The Th2 response also produces IL -9 which 
recruits mast cells.  Mast cells are involved in promoting 
fibrosis, which leads to esophageal strictures.  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 6 
Version: March 14, 2019  
CONFIDENTIAL  Fluticasone MDI  is also topical steroid .  Subjects will swallow at a dose of 880 mcg twice daily (4 puffs of 
a 220 mcg inhaler twice daily) .  The dose for fluticasone MDI has been chosen because this is the most 
commonly used dose in adolescents and adults with EoE, so effect estimates are also a vailable.2, 25, 27, 101  
Subjects randomized to this arm will also be instructed to take 4 mL twice daily of a placebo sl urry of 
sucralose identical in consistency and taste to the OVB.  
1.3 Preclinical Data  
Preliminary data and study feasibility  
The number of EoE cases seen at UNC continues to increase, providing an expanding source population 
for the proposed study. Through th e UNC Center for Esophageal Diseases and Swallowing (CEDAS), 
one of the  largest esophageal referral centers in the country, and two UNC GI procedure units, the PI has 
a rich patient  population to draw from for research. Over the past 7 years,  there has bee n a trend towards 
an increasing number of EoE  cases, including more than 65 new (incident) cases of EoE  annually for the 
past 3 years (Table 3). In addition, the number  of cases in patients 16 years and older, the study 
population for  this trial represents  the majority of these cases, and  is similarly increasing. The PI tracks 
EoE cases in an EoE  Patient Registry and an EoE Clinicopathologic Database. This  latter resource now 
has complete clinical and histologic  information on more than 400 patients with Eo E. 
 
Table 3: Incident cases of EoE at UNC  
Year  Total # of new 
EoE cases  New EoE cases in 
ages ≥16 years  
2006  41 26 
2007  60 39 
2008  56 33 
2009  54 30 
2010  68 36 
2011  70 43 
2012  88 52 
 
In addition, the PI has recently completed a prospective study of  the prevalence of esophageal 
eosinophilia  and EoE in the UNC GI procedure units. Of 173 patients undergoing endoscopy for 
dysphagia, 65 (38%) had  esophageal eosinophilia with ≥ 15 eos/hpf, and 40 (23%) were confirmed to 
have a new diagnosis of EoE after  a PPI trial as per consensus diagnostic guidelines (Table 1).98 This is 
the highest prevalence of EoE yet to be  reported in patients undergoing endoscopy for dysphagia.13-15 
These statistics document how commonly EoE  is seen at our center, given that in 201 2 more than 1000 
upper endoscopies were done for patients with  dysphagia between our two procedure units. Taking these 
data together, it is clear that our unit can support a  steady recruitment of newly diagnosed EoE patients 
into a clinical trial.  
 
Enrollm ent rates in multiple prior prospective studies of EoE at UNC have been excellent, indicating that 
EoE patients seen by the PI and his care team are highly willing to participate in clinical studies . In the 
PI’s prospective study of eosinophil inflammation  and activation funded by an UNC institutional NIH KL2 
award  (KL2 RR025746), a total of 276 patients were approached for screening and 223 (81%) agreed to 
participate.  In the PI’s prospective study of risk factors and biomarkers for diagnosis of EoE funded  by an 
NIH K23 award  (K23 DK90073), a total of 183 subjects have been screened to date with only 8 (5%) 
refusals. For both of  these studies, patients undergoing outpatient upper endoscopy were approached for 
the first time prior to the  procedure, and were remarkably willing to participate. For patients newly 
diagnosed with EoE, rates are even  better. In the randomized study of OVB vs nebulized/swallowed 
budesonide that we conducted (see below), a  total of 34 incident EoE cases were screened and 9 did not 
meet eligibility requirements. Of the remaining 25  cases, none refused participation. Similarly, we are a 
lead site for an industry -sponsored randomized trial of  budesonide syrup vs placebo for treatment of 
adolescents and young adults with EoE. To date we h ave approached 14 patients with EoE for 
participation; only one patient refused to be enrolled. These high  recruitment rates demonstrate the 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 7 
Version: March 14, 2019  
CONFIDENTIAL  feasibility and high likelihood of enrolling EoE patients into the proposed trial  at UNC. To further confirm 
this, we performed a feasibility assessment for the proposed study. A total of 20  patients who met this 
study’s inclusion criteria were approached and 19 (95%) indicated that they  would be willing to be 
randomized.  
 
The PI has helped to standardize methodology f or determining esophageal eosinophil counts, the primary 
histologic outcome used in clinical trials of EoE . Because esophageal eosinophilia is required for 
diagnosis of  EoE and is central to the pathophysiology of the condition, the eosinophil count is the  most 
commonly used  outcome for EoE treatment trials. In early work, the PI identified a number of 
shortcomings in the way in which  eosinophil counts had been determined, including inconsistent 
methodology to quantify cells and variable  definitions of microscope high -power fields.21 To address these 
issues, in collaboration with the study  pathologist (Dr. Woosley), a protocol using digitized histology slides 
to quantify eosinophil counts was  developed and validated. This method has been documented to ha ve 
excellent intra - and inter -observer  reliability for determining cell counts (see appendix and Aim 1 methods, 
below),82 and will form the basis of the  histologic analysis used for the proposed study.    
 
The PI has participated in a multicenter collaborat ion to develop and validate a dysphagia symptom score 
in adults and adolescents with EoE which will be used as a primary symptom outcome in EoE studies . 
While a number of clinical trials of topical steroids in EoE have attempted to assess symptoms as an 
outcome,  none have used a validated symptom score.26, 29, 30, 38, 39, 42 Recently, the PI has participated in a 
multicenter  study that developed and validated the Dysphagia Symptom Questionnaire in adolescents 
and adults with  EoE, the first such measure that  is available.99 This is a daily symptom diary with three 
questions that assess  the frequency and severity of dysphagia. The one and two week  composite scores 
strongly correlate with the frequency of dysphagia, distinguish patients on topical steroids  from those not 
treated (by showing that untreated patients had more dysphagia), and strongly correlate with a  dysphagia 
measure that has been responsive in a previous trial of EoE.30 This instrument will form the basis of  the 
symptom analysis used for the prop osed study.  
 
1.4 Clinical Data to Date  
The PI has conducted the only randomized clinical trial comparing 
two formulations of topical steroids, demonstrating that OVB is 
superior to nebulized/swallowed budesonide for improving 
esophageal eosinophilia . In this study, a visc ous slurry of budesonide 
(OVB) was compared with budesonide that was nebulized and then 
swallowed (NEB).42 This was the first study to compare two topical 
steroid formulations, and also the first to use OVB in an adult 
population. These two formulations we re chosen because OVB has 
been shown to be effective in children and NEB has been shown to 
be effective in adults.29, 30 In addition, because we were assessing 
medication deposition in the esophagus, these formulations were 
amenable to being tagged with a radiotracer.  
 
A total of 25 patients were randomized, 13 to NEB and 12 to OVB, 
and 11 were analyzed in each group. Even with this small sample 
size, the results were dramatic. First, the post -treatment esophageal 
eosinophil counts were significantly lower  in the OVB group 
compared with NEB  (Figure 4) . Second, this response was largely 
explained by the difference in esophageal medication contact time  
(Figure 5) . Specifically, the OVB group had a significantly higher 
esophageal medication contact time (as me asured by the area under 
the esophageal emptying curve) compared with the NEB group. 
Responders in both groups had increased esophageal medication 
contact time compared to non -responders.  
 
Figure 4 :  Histologic response in EoE 
with NEB vs OVB.  Baseline eosinophil 
counts (blue bars) are similar between 
OVB and NEB.  After treatment  (green 
bars) , there is near normalization of the 
eosinophil count in OVB, but no change 
in NEB . 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 8 
Version: March 14, 2019  
CONFIDENTIAL  These d ata strongly implicate the medication formulation as a  key 
variable in the response of EoE to topical steroids, and  provide 
support for our hypothesis that OVB will be more  effective than 
fluticasone MDI, which is analogous to NEB in  that it is a medicatio n 
formulation that is optimized for  pulmonary deposition. We have 
selected fluticasone MDI as a  comparator for OVB rather that NEB 
because fluticasone MDI is the most commonly used topical 
corticosteroid in EoE40 and because patients in our previous trial 
study found  NEB to be a cumbersome delivery method. In fact, of the 
11 patients randomized to NEB, all but one opted to  switch to OVB 
when given the choice at study end. Overall, data from this study 
provide strong justification for  moving forward with the  proposed 
study and show that the assembled research team has already 
successfully  completed a randomized trial of topical steroid use in 
EoE, and therefore will also be able to complete the  proposed study.   
 
The PI has demonstrated that staining esophageal biopsies for MBP, 
eotaxin -3, and mast cell tryptase is technically feasible and has 
substantial diagnostic utility for EoE . We have conducted two case -
control studies of  the utility of using immunohistochem istry (IHC) to 
stain  esophageal biopsies for biomarkers to diagnose EoE. In  the 
first, tryptase was used to stain mast cells, and this  stain had an 
excellent utility for distinguishing EoE and  GERD patients 
(area under the receiver operator  characteristic curve (AUC) 
= 0.84).69 In the second, both  MBP and eotaxin -3 were 
assessed, and the combination  of these two stains had 
outstanding utility for diagnosing  EoE (AUC = 0.96).62 These 
published data show not  only that we have technical 
expertise in staining f or and  quantif ying these biomarkers 
(Figure 6)  but that these  stains have clinical utility for 
diagnosis of EoE.  
 
Preliminary data suggest that increased staining of  eotaxin -3 
and tryptase, but not MBP, in esophageal  biopsies at 
baseline prior to treatment  with topical steroids is associated 
with treatment response.  While no published studies have 
examined MBP, eotaxin -3, and tryptase staining at baseline 
to predict  outcomes of topical steroid therapy, we have 
generated preliminary unpublished data that sug gests that 
these  markers do, in fact, have promise for this. Using stored 
samples in the UNC EoE Registry and Biobank, we  identified 
patients who did (n = 20) and did not (n = 20) have a 
complete histologic response (defined as < 5  eos/hpf) to 
topical ster oid therapy. We stained the baseline (pre -steroid treatment) biopsies for MBP, eotaxin - 3, and 
mast cell tryptase. The results showed that EoE patients who responded to topical steroid therapy had  
Figure 5 :  Representative nuclear scintigraphic 
studies showing cumulative esophageal deposition 
of OVB (A) and NEB (B) over 10 minutes after 
dosing .  OVB coats the esophagus and enters the 
stomach.  NEB has pulmonary uptake with poor 
esophageal deposition.  
Figure 6:   IHC staining for tryptase, MBP, and eotaxin -3 in 
a representative GERD and EoE patient.  In all cases, 
increased staining is seen in EoE.  
Figure 5 :  Representative nuclear scintigraphic 
studies showing cumulative esophageal deposition 
of OVB (A) and NEB (B) over 10 minutes after 
dosing .  OVB coats the esophagus and enters the 
stomach.  NEB has pulmonary uptake with poor 
esophageal deposition.  
Figure 6:   IHC staining for tryptase, MBP, a nd eotaxin -3 in 
a representative GERD and EoE patient.  In all cases, 
increased staining is seen in EoE.  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 9 
Version: March 14, 2019  
CONFIDENTIAL  significantly higher levels of staining for 
eotaxin -3 and t ryptase than did pati ents who 
did not respond (Figure 7) .  This wa s not the 
case with MBP. While the underlying 
mechanism for this finding is not known, we  
hypothesize that patients with a more 
inflammatory milieu in the esophagus as 
evidenced by increased  eotaxin -3 levels and 
the presence of mast cells, are more steroid  
responsive than those who do not have this  
milieu. Because MBP levels correlate closely 
with eosinophil levels,62 and because it is 
thought that the  baseline severity of 
esophageal eosinophilia itself does not predict 
treatment response,2 it is not surpri sing that  
MBP was not associated with treatment 
response.  However, we plan to include MBP 
in our panel of  biomarkers to confirm our 
finding and to provide a  negative control stain. 
These preliminary data provide  justification for 
including Aim 3 in the pro posed study.  
1.5 Dose Rationale  and Risk/Benefits  
OVB dose of 1 mg twice daily is a slurry equivalent to what is used clinically: 1mg/4mL aqueous 
budesonide mixed with 10 g of sucralose. The dose for OVB has been chosen because it is the most 
commonly studied dose, including our prior study, so we can acc urately estimate response rates. 28,29,39,42  
 
Fluticasone MDI dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily) has been chosen 
because this is the most commonly used dose in adolescents and adults  with EoE, so effect estimates 
are al so available.2, 25, 27, 101 
 
For both arms, the slurry will be administered first, the MDI will be administered 15 minutes later, and 
patients will take nothing by mouth for an additional 30 minutes. This schedule is based on our previously 
published esoph ageal emptying data for OVB demonstrating that the half -life for OVB in the esophagus is 
<2 minutes.42 Therefore, the swallowed slurry will be out of the esophagus prior to swallowing the MDI, so 
interaction between the two is not a concern. For both arms,  the treatment period will be 8 weeks. There 
is no placebo arm in this trial because the goal is to compare two active agents and determine which is 
more effective. Of note, no dietary changes or changes in baseline PPI medication dose will be allowed 
during the study period.  
 
There are  risks associated with  the study medications. Both budesonide and fluticasone are 
corticosteroids, and  while these medications have been shown to be well -tolerated in several prior studies 
of EoE when  compared to placebo , 26,29,38,39 adverse  effects are still possible. Local effects such as mouth 
irritation or  sore throat are expected in less than 5% of subjects. Oral candidiasis is also expected in less 
than 5% of  subjects. Candidal esophagitis can occur in 10 -20% of subj ects treated with swallowed 
corticosteroids,  with most cases detected on follow -up endoscopy. This is readily treated with an 
antifungal agent such as  nystatin or fluconazole.  Adrenal insufficiency is a theoretic concern with any 
corticosteroid medication . However, at the doses proposed for this study and with an 8 week treatment 
period, there have been no  reports of adrenal axis suppression in EoE and we do not expect this adverse 
event during the proposed  study.29,38,39,42 Other steroid -related side effe cts such as bone mineral loss, 
cataracts, skin fragility, and  diabetes have not been reported with initial short -term topical steroid use in 
EoE.26,29,38,39,42 It is important  to note that while there are some risks associated with taking these 
medications , for patients diagnosed  with EoE it is likely that they would be treated with one of these 
agents even if they were not participating in  this study, so the medication risks related to the study are 
may not be higher than those of routine clinical  care.  
Figure 7:  EoE patients who responded to topical steroids 
(blue bars) had higher levels of staining for tryptase (A) and 
eotaxin -3 (B) then non -responders (green bars), but this 
was not the case for MBP (C) 
Figure 7:  EoE patients who responded to topical steroids 
(blue bars) had higher levels of staining for tryptase (A) and 
eotaxin -3 (B) then non -responders (green bars), but this 
was not the case for MBP (C) 

Budesonide vs Fluticasone Protocol – TREET Trial   Page 10 
Version: March 14, 2019  
CONFIDENTIAL   
The major direct potential benefit to the patient is that all subjects will receive active medication to treat 
EoE.   Another benefit is that they will receive structured follow -up care and active monitoring for symptom  
recurrence. There is also potential benefit to society is based on scientific knowledge to be gained.  
Eosinophilic esophagitis is a newly recognized disease entity, and data supporting the best approach to  
pharmacologic treatment are lacking in the medical literature.  
 
Given the discussion o f the risks above, many of which are related to testing and treatments that could be  
ordered during the course of routine care were the patients not participating in this study, we feel the risks 
to subjects are acceptable in relation to the potential bene fits. 
2 Study Objectives  
 
Specific Aim 1 . To determine whether viscous budesonide is more effective than fluticasone MDI for 
improving esophageal eosinophil counts and symptoms of dysphagia in patients with EoE after an initial 
treatment course.  
  
Specific Aim 2.  To determine whether treatment with viscous budesonide results in less symptomatic and 
histologic recurrence than fluticasone MDI one year after the initial treatment course.  
 
Specific Aim 3. To determine whether increased baseline staining of esop hageal biopsies for major basic 
protein, eotaxin -3, and mast cell tryptase is associated with histologic response in EoE patients treated with 
topical corticosteroid therapy .   
3 Study Design  
3.1 General Design  
This is a  prospective, randomized, double -blind, do uble-dummy, clinical trial comparing OVB to 
fluticasone MDI for treatment of EoE.  This over study design will generate data for all three Aims, 
reporting will comply with the CONSORT statement100 and will be registered with clinicaltrials.gov.   
 
3.2 Aim 1 Study Outcomes  
The primary outcome for the study  will be the post -treatment maximum eosinophil count (measured in 
eos/hpf). Eosinophil  counts will be determined by the study pathologist both for the screening (baseline) 
and post -treatment exams  using our previously validated protocol.82 In brief, 4 esophageal biopsies will 
be obtained from both the distal  (3 cm above the gastroesophageal junction) and proximal (15 cm above 
the junction) esophagus to maximize  sensitivity of detecting eosinophils.102 On each  biopsy fragment, 5 
high-power fields (hpf area = 0.24mm2) will  be examined and the maximum eosinophil count determined 
at each level. The overall maximum count in the  esophagus will be the primary outcome measure 
because there is no consensus in the liter ature about what  eosinophil cut -point constitutes a “histologic 
non-responder” and different studies use different definitions.25, 103  
 
The co -primary outcome for the study will  be the dysphagia score, as measured by the DSQ.99 This is a 
composite score  generated by a symptom diary completed daily over the two weeks immediately prior to 
randomization (weeks  -2 to 0) such that baseline symptoms take into account any dilation performed at 
the screening endoscopy.  The diary will be repeated over the two weeks  immediately prior to the follow 
endoscopy (weeks 6 -8). Subjects  will be automatically emailed a daily secure link to the three question 
survey to complete each night. The DSQ score (range: 0 -6; higher is more severe) is calculated by 
dividing the sum of t he daily  scores by the number of days in which the diary was filled out. The two -week 
observation period will minimize  the effect of symptom variation.  Subjects will also be given the option of 
completing the diary and questionnaires on paper ; capturing th e date and time of each response.  
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 11 
Version: March 14, 2019  
CONFIDENTIAL  Pre-specified secondary outcomes  include: 1) Endoscopic findings of EoE, including esophageal rings, 
white plaques/exudates, linear furrows, edema/decreased vascularity, and strictures, will be measured 
using the recently  validated EoE Endoscopic Reference Score (EREFS);104 2) Levels of histologic 
response (ie <15 eos/hpf ; 3) Medication compliance as measured by percentage of medication 
appropriately used in each arm ; and 4) symptoms of dysphagia as measured by the Eosinophilic 
Esophagitis symptom Activity Index (EEsAI).  
3.3 Aim 2  Study Outcomes  
Secondary outcomes to be assessed under Aim 2 are:  
- Symptomatic recurrence  will be defined as at least a 1 point increase in the DSQ score over the post -
treatment  score. When th e study coordinator  receives a report of dysphagia, the DSQ will be re -
administered over a 2  week period to determine if the subject meets the criteria for recurrent symptoms.  
 
- Histologic recurrence  will be defined as recurrent esophageal eosinophilia ≥1 5 eos/hpf. This will be 
detected  on the follow -up endoscopy, using the identical biopsy protocol and pathology interpretation 
protocol as  described in Aim 1.  
 
- Other secondary outcomes  will include: 1) Endoscopic findings of EoE measured by the EREFS; and  2) 
Levels  of recurrent esophageal eosinophilia as measured by the maximum eosinophil count (eos/hpf).  
 
3.4 Aim 3 Study Outcomes  
For the IHC sub -analysis to be performed after study completion, the exploratory outcome of h istologic 
response  will be defined as a maximum eosinophil count < 15 eos/hpf on post -treatment biopsies (the 
same definition asin Aim 1).  
For the methods, q uantification  of IHC staining  will be performed with a protocol that mirrors the one used 
for the eosinophil  counts and that has been successfully used in our previous studies.62, 69, 82 The IHC 
glass slides will be scanned, converted to digital slides, and viewed with Aperio ImageScope (Aperio 
Technologies, Vista, CA).82 The maximum density of cells that stained positive for each antibo dy of 
interest in the esophageal epithelial  layer will be quantified  (cells/mm2) in five microscopy fields using the 
Aperio Positive Pixel Count Algorithm  (version 9.1, Aperio Technologies).62, 69, 76 
  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 12 
Version: March 14, 2019  
CONFIDENTIAL  4 Subject Selection and Withdrawal  
4.1 Inclusion Criteria  
1) Age: 16 -80 years  
2) Subject is having a clinically indicated endoscopy (Baseline visit 1) for suspicious EoE and has 
been on BID PPI for at least 8 weeks. OR New diagnosis of EoE as per consensus guidelines.2 
Cases must have symptoms of dysphagia, persistent esophageal eosinophilia ( ≥ 15 eosinophils 
in at least one high -power field)  after 8 weeks of treatment with a twice daily proton -pump 
inhibitor, and other competing causes of esophageal eosinophilia excluded.   
4.2 Exclusion Criteria  
1) Medical instability that precludes safely performing upper endoscopy  
2) Ongoing or recent symptoms of intestinal bleeding (throwing up blood, passing blood in the stool)  
3) Concomitant eosinophilic gastroenteritis (EoG)  
4) Esophageal narrowing or stricturing that will not allow a standard 9 mm upper endoscopy scope to 
pass  
5) Cancer in the esophagus, stomach, or intestine  
6) Prior surgery on the esophagus (e.g., removal of part of the esophagus)  
7) Esophageal varices (dilated blood vessels in the esophagus)  
8) Current use of blood thinners like Plavix or Coumadin that are not stopped prior to endoscopy 
procedures  
9) Corticosteroid exposure within the four weeks prior to the baseline endoscopy .  Exclusionary 
corticosteroid exposure is defined as any swallowed topical steroids for EoE or systemic steroids 
for any condition within the four weeks prior to the baseline endoscopy.  Corticosteroids used for 
asthma or intranasal corticosteroids are not an exclusion and are allowable.  
10) Pregnancy  
11) Inability to read or speak English  
4.3 Subject Recruitment and Screening  
Patients with a new diagnosis of EoE or who are undergoing routine care upper endoscopy for a clinical 
suspicion of EoE will be screened by research personnel . These patients will be identified by  screening 
the endoscopy and CEDAS clinic schedules  or via refe rrals from other physicians . Once a potential 
subject is identified , study personnel  will contact the potential subject to describe the study and gauge 
interest in participating.  Initial contact may be in person or on the phone  using an IRB approved phone  
script .  If the patient is interested in participating, then the study coordinator or other study staff will obtain  
written informed consent  from the subject.  In practice, the vast majority of patients who would qualify for 
this study are seen by the PI i n clinic prior to endoscopy, and this greatly simplifies the logistics of 
identifying patients, enrolling them, and collecting baseline data. At the time of enrollment, the  coordinator 
will collect information about subject demographics, symptom duration, and concomitant atopic conditions 
(asthma, atopic dermatitis, allergic rhinitis/sinusitis, and food allergies ). 
 
4.4 Early Withdrawal of Subjects  
4.4.1  When and How to Withdraw Subjects  
Subjects have the  right to withdraw from the study at any time, for any reason, and without  repercussion.  
The sponsor -investigator, Dr. Evan Dellon, has the right to withdraw a patient from the study in the event 
of an intercurrent illness, adverse event (AE), treatment failure, protocol violation, and for administrative or 
other reasons. An excessive rate of  withdrawals would reduce the amount of data available for analysis 
and limit the ability to interpret the study results; therefore, unnecessary withdrawal of patients should be 
avoided.  
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 13 
Version: March 14, 2019  
CONFIDENTIAL  If a subject withdrawals prematurely, either due to voluntary withd rawal or discontinuation by the sponsor -
investigator, Dr. Evan Dellon, then they will be asked to return for a final visit to return unused study drug 
as well as to complete safety assessments (adverse events).  
4.4.2  Lost to Follow -Up 
A subject will be consider ed lost to follow -up after documentation has been made of at least two 
documented attempts to contact (via phone or email).  At that point a certified letter should be mailed to the 
subject’s home address.  If there is still no response after the certified  letter is delivered, then the subject 
will be withdrawn from the study as lost to follow -up. 
4.4.3  Data Collection and Follow -up for Withdrawn Subjects  
Patients who withdraw prematurely from the study may be asked to complete an end of study visit per the 
study  procedures.  In addition, any ongoing adverse drug reactions or study -related adverse events will be 
followed until resolution or documentation of why there will be no resolution if the event will be ongoing.  
5 Study Drug s  
5.1 Description  
Oral viscous budesoni de (OVB) topical steroid slurry 1 mg/4 mL aqueous budesonide mixed wit h 10g of 
sucralose .  At total of  300mL of slurry will be provided to the patient in a 16oz plastic bottle  every 4 weeks 
during the 8 week treatment period .  For the purposes of compoundi ng the medication to be dispensed as 
a one -month supply, the constituent elements of aqueous budesonide are combined in bulk with 
sucralose to yield the necessary concentration and consistenc y.  The p lacebo oral suspension  will also be  
300mL  of an indistin guishable solution also provided  in a 16oz. plastic bottle  every 4 weeks during the 8 
week treatment period .  
 
Fluticasone MDI will be provided in a 220 mcg metered dose inhaler  that has 120 actuations .  Subjects 
will receive 2 MDIs every 4 weeks during the 8 week treatment period.  As similar number of placebo 
inhalers will be provided as well.  For the inhalers, the UNC IDS pharmacy will prepare and blind these.  
All inhalers will be provided in a feat ureless white plastic shell with no labels.  The containers with 
medication or placebo will also have no labels, and will be sealed inside the container with tamper -proof 
tape.  
5.2 Treatment Regimen  
Arm 1: OVB 1 mg  swallowed at a dose of 1mg twice daily and p lacebo inhaler 4 puffs twice daily for 8 
weeks.    
 
Arm 2: Fluticasone 220 mcg MDI is swallow ed at a dose of 880 mcg twice daily (4 puffs of a 220 mcg 
inhaler twice daily)  and placebo slurry 4mL twice daily  for 8 weeks .   
5.3 Method for Assigning Subjects to T reatment Groups  
Subjects will be randomized in 1:1 fashion to either OVB + placebo inhaler or fluticasone  MDI + placebo 
slurry using a blocked randomization protocol with computer -generated variable block sizes.  The 
randomization sequence will be provided to the UNC investigational drug service (IDS) and allocation will 
be concealed from all investigators,  subjects, and data analysts. The IDS will ensure that all study 
medications are appropriately blinded.  At the time of randomization (study visit 2; Figu re 8), the study 
coordinator  will be provided with the appropriate study medications for the patient, but will not know the 
allocation.  
5.4 Preparation and Administration of Study Drug  
Triangle Compounding Pharmacy will provide OVB  1mg/4ml aqueous s uspension and placebo 
suspension  to the UNC IDS .  The OVB will be the equivalent of a  slurry of 1mg/4mL aqueous budesonide 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 14 
Version: March 14, 2019  
CONFIDENTIAL  mixed with 10g of sucralose.  The placebo OVB slurry will be aqueous sucralose. Triangle Compounding 
Pharmacy will provide all of the necessary  ingredients and devices to compound the medications , such 
that they are indistinguishable by sight, appearance, and taste .  For the purposes of compounding the 
medication to be dispensed as a one -month supply, the constituent elements of aqueous budesonid e are 
combined in bulk with sucralose to yield the necessary concentration and consistenc y.  The medications 
will be prepared in a powder containment hood following USP 795 guidelines.  The UNC IDS will 
purchase fluticasone MDI, and the PI has purchased th e equivalent placebo inhalers and has provided 
them to the IDS.  The IDS will then blind the inhalers, as noted above.  All study dr ug and placebos will be 
stored and dispensed from the UNC IDS.  UNC IDS will determine randomization and dispense blinded 
study drug and placebo to a study coordinator who will then dispense to the subject.   
 
There may be instances in which the participation of an eligible subject is limited only by the ability to 
come to the site for study only visits (Treatment Start Visit 2 ,and/or Mid -Treatment Visit 3. In these cases, 
study drug may be shipped to the subject only after Study PI approval, using the IDS approved Shipping 
Standard Operating Procedure. Visit assessments would be completed by phone, email, and on paper as 
applic able.   
 
UNC Investigational Drug Services: 919 -966-8739  
5.5 Subject Compliance Monitoring  
Budesonide m edication compliance will be  measured by residual OVB slurry remaining  in the bottle .  
Study coordinator will measure the amount and calculate volume remaini ng to compare to expected 
volume remaining.  T he fluticasone medication compliance will be measured using an  actuation counter 
as well as by weight of the inhaler before and after use . Medication compliance will be assessed at the 
mid-treatment visit, and subjects who are non -compliant will be trained on appropriate study medication 
dosage and counseled on the importance of being compliant  with the study medication .  Medication 
compliance will also be assessed at the end of treatment visit.   
5.6 Prior and Concomitant Therapy  
All past and current  EoE medical therapies ( including medication, dilation, etc .) will be collected  along 
with all current concomitant medications .  Any swallowed topical corticosteroid exposure  for EoE or 
systemic steroids for any cond ition within the 4 weeks prior to baseline EGD and during the treatment 
phase are not permitted for the study.   No dietary changes or changes in baseline PPI medication dose 
will be allowed during the study period.  
5.7 Packaging  and Labeling  
UNC IDS will dispense  active study medication and placebo .  Specifically , they will provide the pre -mixed  
16oz bottles containing  300mL of OVB slurry , the ident ical-tastin g 16oz bottles containing 300mL OVB 
placebo slurry, the 220mcg  fluticasone inhaler , and  the placebo inhaler.   All inhalers will be provided in a 
featureless white plastic shell with no labels.  The containers with medication or placebo will also have no 
labels, and will be sealed inside the container with tamper -proof tape.  Based on the bli nded 
randomization schedule, IDS will assemble and label subject drug kits to include  either :  
 
1 16oz bottle  of OVB slurry with 1 measuring device (syringe) and 2 placebo  MDIs or  
 
1 16oz bottle of placebo with 1 measuring device  (syringe)  and 2 fluticaso ne MDIs    
 
All investigational products  dispensed for this study  will be in compliance with labeling requirements per 
21CFR312 and include the following statement:  “Caution: New Drug -Limited by Federal law to 
investigational use”  
 
In addition, product labeling will include:  
 IDS contact information  
 Study IRB number   Study IDS number  
 Subject medical record number  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 2 
Version: March 14, 2019  
CONFIDENTIAL   Subject name  
 Dosing instructions  
 Drug e xpiration date  
 Prescription number   Lot number  
 Quantity  
 Number of refills  
 Pharmacist information  
 
Sample labels are provided below.  
 
IP Label:  
 
 
  

Budesonide vs Fluticasone Protocol – TREET Trial   Page 1 
Version: March 14, 2019  
CONFIDENTIAL  Bag Label:  
 
 
5.8 Blinding of Study Drug   
UNC IDS will implement the blinding of the study drugs.  All study medication will be labelled with unique 
study identification numbers, and the only link between the study ID and the randomization sequence will 
be kept on file by the IDS.  In this manner, study subjects and all other study personnel (in vestigators, 
endoscopists, nurses, statisticians, and study staff) will remain masked as to allocation . 
5.9 Receiving, Storage, Dispensing and Return  
5.9.1  Receipt of Drug Supplies  
Triangle Compounding Pharmacy will deliver OVB and OVB placebo to IDS  as patients are  enrolled in the 
study .  Upon receipt of the of the study treatment supplies, IDS will  inventory the drug and  a drug receipt 
log will be filled out and signed by the person accepting the shipment.  IDS study staff will count and 
verify  that the shipment co ntains all the items noted in the shipment inventory.  Any damaged or unusable 
study drug in a given shipment (active drug or comparator) will be documented in the study files.   
5.9.2  Storage  
All slurry  and inhalers will be stored at room temperature in the IDS . 
5.9.3  Dispensing of Study Drug  
Regular study drug reconciliation will be performed to document drug assigned, drug consumed, and drug 
remaining.  This reconciliation will be logged on the drug accountability  form, and signed and  dated by 
IDS. UNC IDS is responsible for maintaining all drug accountability including receipt, dispensation, and 
destruction.  
5.9.4  Return or Destruction of Study Drug  
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and 
drug remaining.  This reconciliation will be logged on the drug reconciliation form, signed and dated.  Any 
discrepancies noted will be investigated, resolved, and documented prior to return or destruction of 
unused study drug.  Drug destroyed on site will be documented in the study files .  UNC IDS is responsible 
for maintaining all drug accountability including receipt, dispensation, and destruction.  
 
  

Budesonide vs Fluticasone Protocol – TREET Trial   Page 2 
Version: March 14, 2019  
CONFIDENTIAL  6 Study Procedures  
 
 
 
Figure 9.  Study overview of procedures at each visit.  Baseline Visit:  Clinically indicated routine care EGD 
to determine eligibility . Treatment  Start Visit : If subject is eligible, subject is randomized and  starts study 
medication.   End of Treatment Visit:  Clinically indicated routine care EGD to determine response to 
treatm ent.  Follow -up Phase : No study medication taken ; subject symptoms are assessed by phone calls  
or via email . Study End : Occurs 60 weeks post Treatment Start Visit  or when dysphagia symptoms recur.   
Of note, all CFRs will be entered in a custom electronic d ata capture and management system designed 
expressly for this trial.  
 
6.1 Case Identification  
During case identification , eligibility is assessed (based on inclusion/exclusion criteria) and those eligible 
and interested in participating will be consented durin g the Baseline Visit .  Potential cases will be 
identified by screening the endoscopy and CEDAS clinic schedules.  This will require approval of a limited 
HIPAA waiver to access the personal health information (PHI) of potential research subjects prior to t heir 
formal enrollment during Baseline Visit.     
 
6.2 Baseline Visit (Visit 1)  
The baseline visit is a clinically indicated and clinically scheduled EGD appointment that is performed per 
routine care.  The subject is responsible for all associated costs of t he EGD.  

Budesonide vs Fluticasone Protocol – TREET Trial   Page 3 
Version: March 14, 2019  
CONFIDENTIAL   
The following procedures will be completed during the baseline visit:  
 Informed consent  
 Inclusion/exclusion criteria review to determine e ligibility  
 EoE medical history review and demographics collection  
 Concomitant medications collected  
 EGD with  EREF score and biopsies for pathology , per routine care  
 Sample  collection, research related  
 Adverse events noted  
 Daily Symptoms Questionnaire (DSQ) administration – DSQ will be explained and subject will be 
instructed to begin completing daily entries in the evening for 2 weeks  after receipt of pathology 
results and confirmation of eligibility by Dr. Dellon  
 
The Baseli ne Visit Case Report Form (CRF) will be completed by the study coordinator.  This form 
captures demographics including race, ethnicity, gende r, and date of birth, adverse events, EoE medical 
history including documentation of endoscopic procedures to date as well as pathology findings and 
concomitant medications related to EoE  and current concomitant medications . CRF will also include EGD 
data with EREF S score .    The Pathology CRF will be completed by the study pathologist.  This form 
captures eosinophil counts  and associated histologic findings . 
 
Patients may also be identified after routine care EGD by the study physician or a UNC GI colleagu e. 
Patients that are referred will be contacted by Dr. Dellon to discuss the option to participate in EoE 
research studies.  If subjects have already had a confirmatory EGD for EoE, subjects may be consented 
into the study by phone and email; sending a sign ed consent form to study personnel before beginning 
DSQ. See section 6.2.1 for details. Pathology review will occur using previous clinical or research 
samples.   
6.2.1  Consenting Procedure  
If a subject is screened eligible and interested in the study, the subjec t will be consented on the study 
prior to any study procedure. W ritten informed consent will be obtained by qualified study personnel.  
Documentation of the consent process will be maintained in the subject’ s research record.  
 
Subjects  will be given ample time to review the consent document and ask any questions they may have.  
A copy of the written consent form will be provided to the subject  and the original maintained in the 
subject ’s research record.   
 
If subjects  meet all inclusion and none of the exclusion criteria and consent to the study, they will be 
enrolled in the study.  Subjects will be a ssigned a unique subject code.   
 
If a previous EGD result is being used for eligibility purposes, consent will be obtain ed before all other 
Baseline study procedures. Subjects will be provided the consent form by mail or email and the consent 
interview will be conducted by telephone while the subject can read the consent form during discussion. 
The subject will then sign an d date consent forms and email, mail, or return signed copy at next visit. The 
subject will be provided with a staff signed copy of the consent form.  
 
6.2.2  Biopsy Collection and Processing , Research Related  
Biobanking will be performed during this study to arc hive specimens for future research purposes.  During 
the clinically indicated EGD, clinical biopsies will be obtained  for pathology  assessment . In addition, 4 
research -specific biopsies will be obtained from each of the following locations:  Distal esophag us (3cm 
from TGF), middle esophagus (8cm from TGF), and proximal esophagus (13cm from TGF). Additionally, 
2 research -specific biopsies will be obtained from the duodenum, and 2 research -specific biopsies will be 
obtained from the stomach (1 from antrum, 1 from body).  The 4 distal biopsies will be separated into 4 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 4 
Version: March 14, 2019  
CONFIDENTIAL  cryovials: 2 filled with formalin for histology, 1 filled with RNALater, and 1 empty to be frozen immediately 
in liquid nitrogen.        
 
 
Cryovial depiction:  
 
 
 
Research Related Biopsy Collection Protocol:  
 
Biopsy Location  Description  Processing/L abeling Instructions  
4 distal esophageal  4 single biopsies 
3cm from GEJ  
  2 formalin: Label:  PID1_eh2,3_d4_date5 and 
PID_eh_d2 _date  
 1 RNALater:  Refrigerate, store long term in -
80deg.F  Label:  PID_er_d _date  
 1 frozen: Label:  PID_ef_d _date  
4 mid esophageal  4 single biopsies 
8cm from GEJ   1 formalin: Label:  PID_ eh_m _date  
 1 RNALater: Label:  PID_er_m _date  
 2 frozen: Label:  PID_ef_m _date  and 
PID_ef_m2 _date  
4 proximal 
esophageal  4 single biopsies 
13cm from GEJ   2 formalin: Label:  PID_eh_p _date  and 
PID_eh_p2 _date  
 1 RNALater: Label:  PID_er_p _date  
 1 frozen: Label:  PID_ef_p _date   
Figure 10. Research related biopsy tissue collection outline.  Specimen labels include: participant 
identifier1_tissue type2_ fixitive/sample processing3_ esophageal location4_date collected5   
 
1participant identifier (PID)  
2tissue type: “e” is esophageal  
3fixitive /sample processing: r, h, or f where “r” is RNALater, “h” is histology/formalin, and “f” is frozen/empty 
cryovial  
4esophageal location: d, m, or p where “d” is distal, “m” is middle, and “p” is proximal  
5date collected: MMDDYYYY  
 
A reduced number of biopsies may be collected at the discretion of the endoscopist performing the 
procedure.  Biopsy samples missed will not be considered protocol deviations or violations.  
6.2.3  Blood Sample Collection and Processing   
Blood tube  Processing /Labeling Instructions  
2 red top serum 
separators  Centrifuge, aliquot serum into 9 cryovials, store in refrigerator and transfer 
to -80 
Label : PID_s 1, PID_s2, PID_s3, etc.  
1 yellow top  plasma 
buffy separator  Centrifuge , aliquot plasma into 9 cryovials  
Label : PID_p 1, PID_p2, PID_p3, etc.  

Budesonide vs Fluticasone Protocol – TREET Trial   Page 5 
Version: March 14, 2019  
CONFIDENTIAL  buffy into 1 cryovial  
Label : PID_b  
1 purple top  whole blood  Aliquot whole blood into 5 cryovials  
Label : PID_w  
1 PAXgene blood RNA  Store PAXgene tube upright at room temperature for a minimum of 2hrs and 
maximum of 72hrs bef ore transferring to refrigerator then  freezer  
Label : PID  
 
Missed blood samples are allowable, and will not be considered protocol deviations or violations.  
 
Urine or saliva samples may be collected for future testing at Enrollment, End of Treatment, and Study 
End Visits.  
6.3 Treatment Start (Visit 2)  
At treatment start, the subject will come for a study visit, and the following procedures will be performed:  
 Inclusion/exclusion criteria will be reviewed  
 TREET Trial Questionnaire , completed by subject by email (or provided on paper)  
 EEsAI Questionnaire, complete by subject on paper  
 Study Medications dispensed to subject - the subject  will be provided with specific 
instructions about how to use the medications and the timing of administration.  
Additionally, an in formation sheet will be provided with this information.   
 Prior to this visit, the coordinator will receive the set of study medications from the 
IDS that are labelled and coded for that patient, according to the randomization 
scheme.  The coordinator, sub ject, and all study personnel remain blinded to 
treatment allocation.  If determined applicable by the Study PI, the medication can 
be mailed to the subject with confirmation of receipt provided to the study staff.  
 
Mid treatment (visit 3) and end of treatm ent (visit 4) appointments will be scheduled.  The Treatment Start 
CRF will be completed by the Study Coordinator.  
6.4 Mid-treatment ( Visit 3)  
At the mid treatment visit, the subject will come for a study visit, and the following procedures will be 
performed:  
 Adverse Events noted  
 Subject will return used medications  
 The coordinator will assess compliance based on subject report, and identify any barriers to 
compliance with the subject, including retraining on medication administration if necessary  
 Coordinator will measure the remaining medications returned for compliance assessment, as 
noted above.   
 Study medications dispensed to subject. Prior to this visit, the coordinator will receive the set of 
study medications from the IDS.  If determined applicable by the Study PI, the medication can be 
mailed to the subject with confirmation of receipt provided to the study staff.  
 
The mid -treatment CRF will be completed by the Study Coordinator.  
6.5 End of treatment (Visit 4)  
This visit is similar to the treatment start v isit.  It is a clinically indicated and clinically scheduled EGD 
appointment that is performed per routine care for follow -up of treatment response.  The subject is 
responsible for all associated costs of the EGD.  
  
The following procedures will be comple ted during the baseline visit:  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 6 
Version: March 14, 2019  
CONFIDENTIAL   EGD with EREF score and biopsies for pathology, per routine care  
 Sample collection , research related  
 Adverse events noted  
 Daily Symptoms Questionnaire (DSQ) administration confirmation – DSQ will have been sent 2 
weeks prior to the endoscopy.  
 TREET Trial follow -up questionnaire  and the EEsAI,  will be completed by subject  
 Subject will return used medications  
 The coordinator will assess compliance based on subject report  
 Coordinator will measure the remaining medications return ed for compliance assessment, as 
noted above.  
 
The Follow -up Visit Case Report Form (CRF) will be completed by the study coordinator. This form 
captures adverse events, and EGD data with EREFS score.    The Pathology CRF will be completed by 
the study pat hologist.  This form captures eosinophil counts and associated histologic findings.  
 
After this visit, the PI will review biopsy results.  Subjects who do not have a histologic response (defined 
by <15 eos/hpf) will be exited from the study and can resume routine clinical care.  Subjects with a 
histologic response will continue on in the follow -up phase of the study, and will be observed without any 
study medication.  
6.6 Follow -up phone calls and emails  
During the follow -up phase, subjects will receive automate d email follow -up questions from the electronic 
data management system at weeks 12, 20, 30, 40, and 50.  They will also be instructed to contact study 
staff with any recurrent symptoms or issues.  Participation in this phase will last up to one year (study  
week 60) or until symptoms recur, whichever is first.  During the follow -up phase, the patients will be 
contacted by email and/or phone five times by the study staff to screen for adverse events and symptom 
recurrence.  If there is symptom recurrence, the  patients will fill out a repeat DSQ, and then will proceed 
to endoscopy .  If there is no symptom recurrence, the patients will proceed to surveillance endoscopy in 1 
year (see section 6.7).   
6.7 Study end  (Visit 5) 
This visit occurs if symptoms have recurred during the 1 year follow -up phase, or at study week 60, 
whichever comes first.  This visit is similar to the treatment start visit.  It is a clinically indicated and 
clinically scheduled EGD appointment that is p erformed per routine care for follow -up of treatment 
response.  The subject is responsible for all associated costs of the EGD.  
 
The following procedures will be completed during the baseline visit:  
 Concomitant medications collected  
 EGD with EREF S score a nd biopsies for pathology, per routine care  
 Sample  collection, research related  
 Adverse events noted  
 Daily Symptoms Questionnaire (DSQ) administration confirmation – DSQ will have been sent 2 
weeks prior to the endoscopy.  
 TREET Trial follow -up questionnair e 
 EEsAI  questionnaire  
 Symptom assessment  
 
The End -of study Case Report Form (CRF) will be completed by the study coordinator. This form 
captures adverse events, and EGD data with EREFS score.    The Pathology CRF will be completed by 
the study pathologist.   This form captures eosinophil counts and associated histologic findings.  
 
After this procedure, the subject has completed the study and will return to routine care with their referring 
provide r. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 7 
Version: March 14, 2019  
CONFIDENTIAL  7 Statistical Plan  
7.1 Sample Size Determination  
The overall study is powered for the co -primary histologic and symptom outcomes .  Based on estimates 
of histologic improvements from our study of topical budesonide formulations as well as the other  
published studies of topical steroids in adults and children (Table 4),26, 27, 29, 39, 41, 42, 101, 105 we estimate that 
average baseline maximum eosinophil counts will be 80 eos/hpf a nd that average post -treatment 
maximum eosinophil counts will be 10 ± 10 eos/hpf in the OVB arm and 20 ± 20 eos/hpf in the fluticasone 
MDI arm.  To detect this different with a power of 0.9, 53 subjects per arm are needed (Table 5).  
Assuming a drop -out ra te of 15%, which is what we observed in our budesonide trial,42 we will randomize 
to treatment  61 subjects in each arm, for a total of 122.   This sample size will also allow us to detect with 
a power of 0.9 a DSQ difference of as little as 1 point, which was the average difference between those 
patients on topical steroids and those not on topical steroids in the validation study of the DSQ.99  This is 
a clinically significant difference equivalent to having one day less of dysphagia per week.  We are 
planning a 36 month enrollment phase , which ave rages to 40 subjects per year.  This is substantially less 
than the number of incident cases in the study age range diagnosed at UNC in the last two years (Table 
3) and is a realistic goal.   
 
For Aim 2, b ased on estimates in the literature, we would expect  at least 80% of subjects in the OVB 
arm,29, 30, 39, 42 and at least 50% of subjects in the fluticasone MDI arm,26, 27, 41, 101, 105 to have a 
symptomatic and histologic response (<15 eos/hpf) after the initial treatment period.  Therefore, 
approximately 42 subjects in the OVB arm and 27 subjects in the MDI arm will enter the follow -up period.  
There are no prospective comparative data on symptomatic or histologic recurrence rates for these two 
medications.  However, based on these sample sizes and estimating a recurrence rate of 80% in the MDI 
group, we would be able to detect a hazard ratio for symptomatic recurrence of 0.43 or lower with a 
power of 0.8 for OVB compared with MDI.  Similarly, for histologic recurrence, we would be able to detect 
a difference as low as 36% with a power of 0.8 for OVB compared with MDI.  
 
For Aim 3, b ased on estimate s in the literature and our own preliminary data, we expect 60% of subjects 
in the OVB arm,29, 39, 42 and 40% of subjects in the MDI arm,26, 27, 41, 101, 105 to have a complete histologic 
response of <5 eos/hpf.  Therefore, we expect a total of 53 histologic responders and 53 non -responders.  
With this sample size, we will be able to detect a differen ce between the responders and non -responders 
as low as 100 cells/mm2 for tryptase staining and 1250 cells/mm2 for eotaxin -3 staining with a power of 
0.9.  Both of these values are less than or equivalent to the differences we observed in our preliminary 
data.  While we do not expect to see a difference in MBP staining, with this sample size we would be 
powered to find a difference of 750 cells/mm2 or greater if such a difference exists  
7.2 Statistical Methods  
For Aim 1, t o test whether OVB is more effective tha n fluticasone MDI for improving eosinophil counts, the 
mean post -treatment maximum eosinophil count will be compared between the OVB and MDI groups 
using a two -sample t -test.  The pre - and post -treatment counts will also be compared within study groups 
using a paired t -test.  To test whether OVB 
is more effective than MDI for improving 
symptoms of dysphagia, the mean DSQ 
scores will be compared between the OVB 
and MDI groups using a two -sample t -test, 
and within groups using a paired t -test.  For 
the second ary outcomes, means will be 
compared for the post -treatment endoscopy 
score with t -tests, and proportions will be 
compared with chi -square for the levels of 
histologic response.  For all analyses, if data 
distributions are not normal, non -parametric 
testin g will be used. All analyses will be by intention -to-treat and performed using SAS (version 9.2).  All Table 5:  Sample size calculations for primary histologic outcome  
Post-treatment 
eosinophil counts (mean 
eos/hpf)*     
OVB  MDI α Power  N per group  
15 20 0.05 0.8 157 
10 20 0.05 0.8 40 
5 20 0.05 0.8 18 
15 20 0.05 0.9 211 
10 20 0.05 0.9 53 
5 20 0.05 0.9 24 
*SDs for all OVB and MDI estimates are 10 and 20, respectively  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 8 
Version: March 14, 2019  
CONFIDENTIAL  tests will be two -sided with a significance level set at p < 0.05.  To account for the possibility that baseline 
subject characteristics are unevenly dis tributed between study groups, we will perform an additional 
analysis with multiple linear regression to control for possible confounders including co -existing atopic 
disease (asthma, atopic dermatitis, allergic rhinitis/sinusitis, food allergies), symptom  duration prior to 
diagnosis, esophageal stricture on baseline endoscopy, and esophageal dilation on baseline endoscopy.  
 
For Aim 2, to test whether OVB results in less symptomatic recurrence than fluticasone MDI, survival 
analysis will be performed with t he interval between treatment end (week 8) and recurrent symptoms or 
study end (week 60) as the time of interest.  A Kaplan -Meier curve will be constructed comparing the time 
until symptom recurrence in both study groups using the log -rank test.  Hazard ra tios will be calculated 
using Cox proportional hazards models, and we will adjust for potential confounders including age, 
gender, atopic status, symptom duration prior to EoE diagnosis, and presence of esophageal strictures on 
endoscopy.  To test whether OVB results in less histologic recurrence than fluticasone MDI, the 
proportion of subjects with ≥15 eos/hpf at follow -up endoscopy in each group will be compared using chi -
square.  This analysis cannot be time -dependent because the eosinophil count is not known for all 
subjects until the follow -up exam is complete.  
 
For Aim 3, t o test the hypothesis that elevated levels of eotaxin -3 and tryptase, but not MBP, will predict 
histologic response after treatment with topical steroids, we will perform three identical analyses.  In the 
first, the mean baseline cellular staining for eotaxin -3 will be compared between the responder and non -
responder groups using a two -sample t -test.  This same analysis will be repeated for tryptase and MBP.  
We also plan a multi variable analysis to determine if these biomarkers independently predict response.  
For this, logistic regression modeling will be performed controlling for factors such as age, gender, atopic 
status, symptom duration prior to EoE diagnosis, and presence o f esophageal strictures on endoscopy.  
For the secondary analyses, we will assess staining using other levels of histologic response (partial 
response with 5 -14 eos/hpf and non -response with ≥15 eos/hpf) and by formulation of topical steroid 
(OVB vs flutic asone MDI).  We will also determine if baseline staining was associated with decreased 
post-treatment symptoms of dysphagia measured by the DSQ, and whether the biomarkers correlate with 
each other.  For all analyses, if data distributions are not normal, non-parametric testing will be used. All 
tests will be two -sided with a significance level set at p < 0.05.  
7.3 Subject Population(s) for Analysis  
The subject population for analysis will be by intention -to-treat, and will include all patients who are 
randomiz ed and who complete the protocol to have follow -up data available.  
8 Safety and Adverse Events  
8.1 Definitions  
Unanticipated Problems Involving Risk to Subjects or Others  (UPIRSOs)  
Any incident, experience, or outcome that meets all of the following criteria:  
 Unexpected in nature, severity, or frequency   (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc)  
 Related or possibly related to participation in the research  (i.e. possibly rel ated means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the 
procedures involved in the research,  
 Suggests that the research places  subjects or others at a greater risk of harm (including physical, 
psych ological, economic, or social harm) than was previously known or recognized.  
 
Adverse Event  
An adverse event  (AE) is any untoward or unfavorable medical occurrence in a human subject, including 
any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, experience, or 
disease, temporally associated with the subject’s participation in the re search, whether or not considered 
related to the subject’ s participation in the research.  Adverse events encompass both physical and 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 9 
Version: March 14, 2019  
CONFIDENTIAL  psychological harms . Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal 
results of diagnost ic procedures are considered to be adverse events if the abnormality:  
 results in study withdrawal  
 is associated with a serious adverse event  
 is associated with clinical signs or symptoms  
 leads to additional treatment or to further diagnostic tests  
 is consi dered by the investigator to be of clinical significance  
 
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE that is:  
 fatal 
 life-threatening  
 requires or prolongs hospital stay  
 results in persi stent or significant disability or incapacity  
 a congenital anomaly or birth defect  
 an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance.   They may jeopardize the subject, and may require intervention to prevent one of the 
other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result 
in in-patient hospitalization, or intensive treatment of bronchospasm in an emergency department would 
typically be considered serious.  
 
All adverse events that do not meet any of the criteria  for serious should be regarded as non-serious 
adverse events .  
 
Serious vs. Severe  
The term “severe” is often used to describe the intensity (severity) of a specific event (as in mild, moderate, 
or severe); the event itself, however, may be of relatively minor medical significance (such as severe 
headache).  This is not the same as “serious,” which is based on patient/event outcome or action criteria 
usually associated with events that pose a threat to a patient’s life or functioning.  Seriousness (not sev erity) 
serves as a guide for defining regulatory reporting obligations.  
 
Adverse Drug Reaction (ADR)  
Any adverse event caused by a drug.  An ADR can be considered a “suspected” adverse drug reaction  if 
there is a reasonable possibility that the drug cause d the adverse event.  “Reasonable possibility” means 
there is evidence to suggest a causal relationship between the drug and the adverse event.  
 
Unexpected Adverse Drug Reaction  
An adverse drug reaction, the nature or severity of which is not consistent wit h the applicable product 
information (e.g. package insert or investigator’s brochure).  
 
Adverse Event Reporting Period  
The study period during which adverse events must be reported is normally defined as the period from the 
initiation of any study procedur es to the end of the study treatment follow -up.  For this study, the study 
treatment follow -up is defined as 30 days following the last administration of study treatment.   
 
Preexisting Condition  
A preexisting condition is one that is present at the start o f the study.  A preexisting condition should be 
recorded as an adverse event if the frequency, intensity, or the character of the condition worsens during 
the study period.  
 
  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 10 
Version: March 14, 2019  
CONFIDENTIAL  General Physical Examination Findings  
At screening, any clinically significant a bnormality should be recorded as a preexisting condition.  At the 
end of the study, any new clinically significant findings/abnormalities that meet the definition of an adverse 
event must also be recorded and documented as an adverse event.   
 
Post -study Ad verse Event  
All unresolved adverse events should be followed by the investigator until the events are resolved, the 
subject is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct ea ch subject to report any subsequent event(s) that the subject, or the subject’s 
personal physician, believes might reasonably be related to participation in this study.  The investigator 
should notify the study sponsor of any death or adverse event occurri ng at any time after a subject has 
discontinued or terminated study participation that may reasonably be related to this study.  The sponsor 
should also be notified if the investigator should become aware of the development of cancer or of a 
congenital ano maly in a subsequently conceived offspring of a subject that has participated in this study.  
 
Abnormal Laboratory Values  
A clinical laboratory abnormality should be documented as an adverse event if any one of the following  
conditions is met:   
 The laboratory abnormality is not otherwise refuted by a repeat test to confirm the abnormality  
 The abnormality suggests a disease and/or organ toxicity  
 The abnormality is of a degree that requires active management; e.g. change of dose, 
discontinuation of the  drug, more frequent follow -up assessments, further diagnostic investigation, 
etc. 
 
Hospitalization, Prolonged Hospitalization or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization should be documented and 
reported as a serious adverse event unless specifically instructed otherwise in this protocol.  Any condition 
responsible for surgery should be documented as an adverse event if the condition meets the criteria for 
and adverse event.   
 
Neither the condition, hospitaliza tion, prolonged hospitalization, nor surgery are reported as an adverse 
event in the following circumstances:  
 Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a 
preexisting condition.  Surgery should not be re ported as an outcome of an adverse event if the 
purpose of the surgery was elective or diagnostic and the outcome was uneventful.  
 Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study.  
 Hospitalization or prolonge d hospitalization for therapy of the target disease of the study, unless it 
is a worsening or increase in frequency of hospital admissions as judged by the clinical investigator.  
8.2 Recording of Adverse Events  
At each contact with the subject, the investigato r must seek information on adverse events by specific 
questioning and, as appropriate, by examination.  Information on all adverse events should be recorded 
immediately in the source document, and also in the appropriate adverse event module of the case re port 
form (CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results should 
recorded in the source document, though should be grouped under one diagnosis.  
 
All adverse events occurring during the study period must be recorded.  The clinical course of each event 
should be followed until resolution, stabilization, or until it has been determined that the study treatment or 
participation is not the cause.  Serious adverse events that are still ongoing at the end of the study period  
must be followed up to determine the final outcome.  Any serious adverse event that occurs after the study 
period and is considered to be possibly related to the study treatment or study participation should be 
recorded and reported immediately.  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 11 
Version: March 14, 2019  
CONFIDENTIAL  8.3 Reporting  of Serious Adverse Events and Unanticipated Problems  
Investigators and the protocol sponsor must conform to the adverse event reporting timelines, formats and 
requirements of the various entities to which they are responsible, but at a minimum those event s that must 
be reported are those that are:  
 related to study participation,  
 unexpected, and  
 serious or involve risks to subjects or others  
(see definitions, section  8.1).   
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of the 
initial report includes:  
 Study identifier  
 Study Center  
 Subject number  
 A description of the event  
 Date of onset   Current status  
 Whether study treatment was discontinued  
 The reason why the event is classified as serious  
 Investigator assessment of the association 
between the event and study treatment  
 
8.3.1  Investigator reporting: notifying the study sponsor  
Any study -related unanticipated proble m posing risk of harm to subjects or others, and any type of study -
related serious adverse event, must be reported to the study sponsor by telephone within 24 hours of the 
event.  To report such events, a Serious Adverse Event (SAE) form must be completed by the investigator 
and faxed to the study sponsor within 24 hours.  The investigator will keep a copy of this SAE form on file 
at the study site.  Report serious adverse e vents by phone and facsimile to the PI, and the study coordinator, 
who in turn will communicate to the UNC IRB, and if necessary, NIH.  
 
Within the following 48 hours, the investigator must provide further information on the serious adverse event 
or the unanticipated problem in the form of a written narrative.  This should include a copy o f the completed 
Serious Adverse Event form, and any other diagnostic information that will assist the understanding of the 
event.  Significant new information on ongoing serious adverse events should be provided promptly to the 
study sponsor  
8.3.2  Notifying the UNC IRB 
Dr. Evan Dellon is responsible for reporting adverse events to the UNC IRB per the UNC IRB SOPs for 
reporting adverse events. Federal regulations require investigators to report unanticipated problems 
involving risks to subjects or others to the IR B. Historically, there has been confusion about what needs to 
be reported. OHRP and FDA have issued guidance that clarifies that investigators need only report 
“unanticipated problems involving risks to subjects or others” (or UPIRSOs). The UNC -Chapel Hill  policy is 
based on this guidance. “Adverse events” that are not UPIRSOs are not required to be reported to the IRB.  
8.3.2.1  Differentiating between an UPIRSO and an Adverse Event  
By definition, an UPIRSO is unexpected, whereas an “adverse event” may be anticipated or unanticipated. 
Additionally, an UPIRSO may involve the increased risk of harm —whether or not any actual harm occurred. 
In order to decide which events or circumstances constitute an UPIRSO, it is important to bear in mind the 
following:  
• Not all Adverse Events are UPIRSOs. Only a small subset of “adverse events” occurring in FDA -
regulated clinical trials and other types  of studies constitute UPIRSOs.  Many events that are 
required to be reported to the sponsor or federal agency are not UPIRSOs.  
• An UPIRSO may not be an adverse event. It is possible for an event that does not involve actual 
physical, psychological, social, or economic harm to a research subject or another person 
nevertheless to constitute an UPIRSO that must be reported to the IRB . This is the case if the event 
places subjects or others at increased or different risk of harm, regardless of whether actual harm 
has occurred.  
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 12 
Version: March 14, 2019  
CONFIDENTIAL  There are other types of incidents, experiences and outcomes that occur during the conduct of human 
subjects research that represent UPIRSOs but are not considered adverse events. Some UPIRSOs involve 
social or economic harm instead of the physical or psychological harm associated with adverse events. In 
other cases, UPIRSOs place subjects or others at  risk of ha rm, but no harm occurs. For example, an 
investigator conducting behavioral research collects individually identifiable sensitive information about illicit 
drug use and other illegal behaviors by surveying college students. The data are stored on a laptop 
computer without encryption, and the laptop computer is stolen from the investigator’s car. This is an 
UPIRSO and must be reported because the incident was (a) unexpected (i.e., the investigators did not 
anticipate the theft); (b) related to participation i n the research; and (c) placed the subjects at a greater risk 
of psychological and social harm from the breach in confidentiality of the study data than was previously 
known or recognized.  
Other examples of UPIRSOs that should be reported to the IRB, even though they are not adverse events, 
include:  
• Publication in the literature, safety monitoring report (e.g., DSMB report), interim result, or other 
finding that indicates an unexpected change to the risk/benefit ratio of the research;  
• Breach in confidential ity resulting from a disclosure of confidential information or from lost or stolen 
confidential information;  
• Unresolved complaint of a participant, family member or other individual;  
• Laboratory or medication errors that may involve potential risk to that i ndividual or others;  
• Change in FDA labeling because of adverse consequences or withdrawal from marketing of a drug, 
device, or biologic used in a research protocol;  
• Disqualification or suspension of investigators;  
• Accidental or unintentional change to the IRB-approved protocol that involves risks or has the 
potential to recur;  
• Deviation from the protocol taken without prior IRB review to eliminate apparent immediate hazard 
to a research participant  
• Any deviation from the IRB -approved protocol that increases  the risk or affects the participant’s 
rights, safety, or welfare.  
8.3.2.2  UNC IRB Reporting Timelines  
Reporting is required of all UPIRSOs, including those which may occur after the participant has completed 
or is withdrawn from the study, or following study clos ure. Reporting is completed via IRBIS, UNC’s online 
IRB information system.  
 
Events that meet the criteria for an UPIRSO and are also serious adverse events should be reported to the 
IRB within one (1) week  of the investigator becoming aware of the event.  
 
Any other events that meet the criteria for a UPIRSO should be reported to the IRB within two (2) weeks  
of the investigator becoming aware of the problem.  
 
If the report cannot be completed in its entirety within the required time period, a preliminary re port should 
be submitted. The report should be amended once the event is resolved and/or more information becomes 
available.  
8.3.3  Notifying the FDA  
As the sponsor, Dr. Evan Dellon  is required to report certain study events in an expedited fashion to the 
FDA.  These written notifications of adverse events are referred to as IND safety reports. The following 
describes the safety reporting requirements by timeline for reporting and as sociated type of event  per 
21CFR312.32:  
 
 Within 7 calendar days  
Any study event that is : 
– associated with the use of the study drug  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 13 
Version: March 14, 2019  
CONFIDENTIAL  – unexpected,  
– fatal or life -threatening, and  
 
 Within 15 calendar days  
Any study event that is : 
– associated with the use of the  study drug,  
– unexpected, and  
– serious, but not fatal or life -threatening  
-or- 
– a previous adverse event that was not initially deemed reportable but is later found to fit the 
criteria for reporting (reporting within 15 calendar days from when event was deeme d 
reportable).  
Any finding from tests in laboratory animals that:  
– suggest a significant risk for human subjects including reports of mutagenicity, teratogenicity, 
or carcinogenicity.  
 
Additional reporting requirements  
Sponsors are also required to identif y in IND safety reports all previous reports concerning similar adverse 
events and to analyze the significance of the current event in light of the previous reports.  
 
Reporting Process  
Adverse events requiring reporting to FDA per the above may be submitted on FDA Form 3500A or in a 
narrative format. If supplied as a narrative format, the minimum information to be supplied is noted above 
at the beginning of section 8.3. 
8.4 Unblinding Procedures  
If an AE or other clinical event necessitates unblinding the patient, this decision will be made by the PI in 
consultation with the DSMB.  Actions will be reported to t he UNC IRB and the DSMB.  
8.5 Stopping Rules  
This study does not have stopping rules, and there are no plans for an interim analysis.  
8.6 Medical Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as the construction and implementation of a site data and safety -monitoring plan (see section  
10).  Medical monitoring will include a regular assessment of the number and type of adverse events.  
8.6.1  Independent Data and Safety Monitoring Board  
The DSMB will regularly review interim data to assess co mpliance, monitor toxicity, and recommend 
whether the trial should continue.  Members will be independent experts not otherwise affiliated with the 
trial or UNC as an institution, and will be chosen on the basis of their expertise and scientific rigor.  Th e 
areas of expertise for the DSMB members span the disciplines relevant to the conduct of GI clinical trials, 
including epidemiology, trial design and conduct, and clinical care of EoE patients. The members will be:  
 
Ikuo Hirano (Chair)  
Professor of Medici ne 
Northwestern University  
Chicago, IL  David A. Katzka  
Professor of Medicine  
Mayo Clinic  
Rochester, MN  Gary W. Falk  
Professor of Medicine  
University of Pennsylvania  
Philadelphia, PA  
 
The DSMB will meet via conference call at the beginning of the study, and then at 6 -month intervals until 
the study is complete.  The PI (Dr. Dellon) as well as the study biostatistician (Dr. Galanko) will participate 
in the open portion of the meetings.  If needed, the DSMB’s voting members may then choose to discuss 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 14 
Version: March 14, 2019  
CONFIDENTIAL  issues  in a closed session kept confidential from the investigators.  The DSMB has the responsibility to 
review the research protocol and to evaluate the progress of the trial overall.  It will also evaluate participant 
risk and benefit as the trial progresses, considering evolving scientific discoveries or treatment options that 
may affect the desirability of continued treatment. At the conclusion of each meeting, the DSMB will 
recommend whether the trial be continued.  The specific information it will review in clude: current status of 
study enrollment; level of medication compliance; medication -related adverse events; endoscopy -related 
adverse event; and subject -reported events.  Unexpected serious adverse events will be reported to the 
DSMB between meetings as needed, as well as to the UNC IRB as noted above.  
 
9 Data Handling and Record Keeping  
9.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed 
subject authorization informing the subject of the following:  
 What protected health information (PHI) will be collected from subjects in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains 
the ability to  use all information collected prior to the revocation of subject authorization.  For subjects that 
have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect 
at least vital status (i.e. that the subject is al ive) at the end of their scheduled study period.  
9.2 Source Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  So urce data are contained in source 
documents.  Examples of these original documents, and data records include: hospital records, clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing 
records , recorded data from automated instruments, copies or transcriptions certified after verification as 
being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico -technical departments 
involved in the clinical trial.  
9.3 Case Report Forms  
The study will utilize electronic case report forms (eCRFs).  All data requested on the CRF must be recorded.  
All missing data must be explained  in the comments section of the eCRF.  The electronic data capture 
system (EDC) will maintain an audit trail.  
9.4 Records Retention  
It is the investigator’s responsibility to retain study essential documents for at least 2 years after the last 
approval of a marketing application in their country and until there are no pending or contemplated 
marketing applications in their country or a t least 2 years have elapsed since the formal discontinuation of 
clinical development of the investigational product.  These documents should be retained for a longer period 
if required by an agreement with the sponsor.  In such an instance, it is the resp onsibility of the sponsor to 
inform the investigator/institution as to when these documents no longer need to be retained.  
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 15 
Version: March 14, 2019  
CONFIDENTIAL  10 Study Monitoring, Auditing, and Inspecting  
10.1 Study Monitoring Plan  
This study will be monitored regularly by the coordinator and inve stigator to ensure accurate data entry and 
reporting.    If other agencies choose to monitor the site such as the sponsor (NIH) , FDA,  or institution (UNC),   
then t he Investigator will ensure the monitor or other compliance or quality assurance reviewer is g iven 
access to all the above noted study -related documents and study related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.  
The monitor is responsible for ensuring:  
(a) the rights and well -being of trial participants are protected,  
(b) reported trial data are accurate, complete, and verifiable from source documents,  
(c) the conduct of the trial is in compliance with the currently approved 
protocol/amendments, with GCP, and with the applicable regulator y requirements, and  
(d) data reported are verifiable to support meeting the study objectives.  
Procedures and sources of information:   
Protection of the rights and well -being of study subjects by verifying:  
1. Investigator(s) have adequate qualifications, education and training, and resources 
necessary to conduct the study.  
2. Verify the investigator and his staff follow the approved protocol and all approved 
amendments, if any  
3. The investigator personally conducts or adequately supervises his study staff  
4. Study staff are adequately trained and study functions are delegated to authorized individuals  
5. Written informed consent was obtained before each subject’s participation in the study  
6. Enrollment of only eligible subjects  
7. Subjects are instructed in the proper use , storage and return of the investigational product  
8. Adequate and accurate case histories that record all observations are maintained  
9. Unanticipated adverse events are reported in accordance with the protocol  
 
Trial data are accurate, complete and verifiable  from source documents as verified from review of subject 
file, case report forms, and medical procedures reports  
1. Verify that the investigative staff are performing the specific trial functions in accordance 
with the protocol  
2. Checking the accuracy and com pleteness of case report form entries, source documents 
and other trial related records against each other  
3. Adequate and accurate case histories that record all observations are maintained  
4. All withdrawals and dropouts are properly reported and explained  
5. Investigator is informed of protocol deviations, data entry  errors  and omissions  and 
illegibility  
Study is conducted in compliance with the currently approved protocol/amendments, with GCP, and 
applicable regulatory requirements  
1. Verify the investigator follo ws the approved protocol and all approved amendments, if any  
2. Ensuring that an IRB approval is obtained prior to study initiation and that the IRB is kept 
informed of changes in research activity and unanticipated problems involving risk to 
subjects  
3. Determi ne if investigator is maintaining essential documents in a regulatory binder  
4. Investigational product is properly procured, stored and destroyed accordingly  
5. Documenting deviations from the protocol, SOPs, GCP and applicable requirements to 
the investigator and taking appropriate action designed to prevent recurrence of the 
detected deviations.  
6. Monitor will provide a written report after each study visit or study visit communication  
 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 16 
Version: March 14, 2019  
CONFIDENTIAL  10.2 Auditing and Inspecting  
The investigator will permit study -related monitorin g, audits, and inspections by the IRB, the sponsor, 
government regulatory bodies, and University compliance and quality assurance groups of all study related 
documents (e.g. source documents, regulatory documents, data collection instruments, study data et c.).  
The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by government 
regulatory authorities and applicable University compliance and quality assurance offices.  
11 Ethical Considerations  
This trial will be conducted in compliance with institutional review board  (IRB) and ICH GCP Guidelines 
including Title 21 Part 56 of the United States of America (USA) Code of Federal Regulations (CFR) relating 
to IRBs and GCP as described in the United States Food and Drug Administration (F DA) CFR (21 CFR § 
50, 56, 312)  in accordance with applicable ICH regulations regarding clinical safet y data management (E2A, 
E2B(R3)), with ICH regulations regarding scientific integrity (E4, E8, E9 and E10) and with FDA regulations 
regarding financial disclosure (21 CFR § 54). In addition this trial will adhere to all local regulatory 
requirements, and r equirements for data protection.  
 
This protocol and any amendments will be submitted to a properly constituted independent Ethics 
Committee (EC) or Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal 
approval of the study conduct.  The decision of the EC/IRB concerning the conduct of the study will be 
made in writing to the investigator and a copy of this decision will be provided to the sponsor before 
commencement of this study.  The investigator should provide a lis t of EC/IRB members and their affiliate 
to the sponsor.  
 
All subjects for this study will be provided a n IRB -approved  consent form describing this study and providing 
sufficient information for subjects to make an informed decision about their participatio n in this study.  The 
formal consent of a subject, using the EC/IRB -approved consent form, must be obtained before that subject 
undergoes any study procedure.  The consent form must be signed by the subject or legally acceptable 
surrogate, and the investig ator-designated research professional obtaining the consent.  
12 Study Finances  
12.1 Funding Source  
This study is funded by a grant from NIH (R01 DK101856).  
12.2 Conflict of Interest  
Any investigator who has a conflict of interest with this study (patent ownership, roy alties, or financial gain 
greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by a properly 
constituted Conflict of Interest Committee with a Committee -sanctioned conflict management plan that has 
been reviewed an d approved by the study sponsor prior to participation in this study.  All University of North 
Carolina  investigators will follow the University conflict of interest policy.  
12.3 Subject Stipends or Payments  
Subject incentives  are graded, with increasing paymen ts for each phase of the study to maximize subject 
retention in the trial ($25 at the baseline visit, $25 at randomization, $50 at the mid -treatment visit, $50 at 
treatment end, and $50 at the study end/recurrent symptoms visit).  Subjects are paid only fo r visits 
completed. This total of $200 per subject for 122 subjects randomized to treatment will be distributed over 
the 36 month enrollment period.   
Budesonide vs Fluticasone Protocol – TREET Trial   Page 17 
Version: March 14, 2019  
CONFIDENTIAL  13 Publication Plan  
Neither the complete nor any part of the results of the study carried out under this prot ocol, nor any of the 
information provided by the sponsor for the purposes of performing the study, will be published or passed 
on to any third party without the consent of the study sponsor.  Any investigator involved with this study is 
obligated to provid e the sponsor with complete test results and all data derived from the study.  
  
Budesonide vs Fluticasone Protocol – TREET Trial   Page 18 
Version: March 14, 2019  
CONFIDENTIAL  14 References  
 
1. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, 
Straumann A, Rothenberg ME. Eosinophilic esophagitis  in children and adults: a systematic review 
and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342 -
63. 
2. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins 
MH, Dellon ES, Doh il R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz 
JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer 
A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, 
Acev es SS. Eosinophilic esophagitis: Updated consensus recommendations for children and 
adults. J Allergy Clin Immunol 2011;128:3 -20.e6.  
3. Desai TK, Stecevic V, Chang CH, Goldstein NS, Badizadegan K, Furuta GT. Association of 
eosinophilic inflammation with es ophageal food impaction in adults. Gastrointest Endosc 
2005;61:795 -801. 
4. Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. 
Gastroenterology 1978;74:1298 -1301.  
5. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A 
distinct clinicopathologic syndrome. Dig Dis Sci 1993;38:109 -16. 
6. Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, Locke GR, 3rd, 
Talley NJ. Epidemiology of eosinophilic esophagitis over t hree decades in Olmsted County, 
Minnesota. Clin Gastroenterol Hepatol 2009;7:1055 -61. 
7. Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M, Beglinger C, Schoepfer AM. 
Escalating incidence of eosinophilic esophagitis: A 20 -year prospective, popul ation -based study in 
Olten County, Switzerland. J Allergy Clin Immunol 2011;128:1349 -1350 e5.  
8. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004;351:940 -1. 
9. Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, Shaheen NJ. Clinical, 
endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal 
reflux disease. Clin Gastroenterol Hepatol 2009;7:1305 -1313.  
10. Katzka DA. Eosinophilic esophagitis. Curr Opin Gastroenterol 2006;22:4 29-32. 
11. Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling -Sternevald E, Vieth 
M, Stolte M, Walker MM, Agreus L. Prevalence of oesophageal eosinophils and eosinophilic 
oesophagitis in adults: The population -based Kalixanda study.  Gut 2007;56:615 -20. 
12. Zink DA, Tosch K, Chang C, Desai TK. Prevalence of esoinophilic esophagitis among patients 
presenting with dysphagia to a community gastroenterology practice. Am J Gastroenterol 
2005;100:S34 (A35).  
13. Prasad GA, Talley NJ, Romero Y, Arora AS, Kryzer LA, Smyrk TC, Alexander JA. Prevalence and 
Predictive Factors of Eosinophilic Esophagitis in Patients Presenting With Dysphagia: A 
Prospective Study. Am J Gastroenterol 2007;102:2627 -32. 
14. Mackenzie SH, Go M, Chadwick B, Thomas K, Fan g J, Kuwada S, Lamphier S, Hilden K, Peterson 
K. Clinical trial: eosinophilic esophagitis in patients presenting with dysphagia: a prospective 
analysis. Aliment Pharmacol Ther 2008;28:1140 -6. 
15. Veerappan GR, Perry JL, Duncan TJ, Baker TP, Maydonovitch C,  Lake JM, Wong RK, Osgard EM. 
Prevalence of Eosinophilic Esophagitis in an Adult Population Undergoing Upper Endoscopy: A 
Prospective Study. Clin Gastroenterol Hepatol 2009;7:420 -426. 
16. Sperry SL, Crockett SD, Miller CB, Shaheen NJ, Dellon ES. Esophageal  foreign -body impactions: 
epidemiology, time trends, and the impact of the increasing prevalence of eosinophilic esophagitis. 
Gastrointest Endosc 2011;74:985 -91. 
17. Diseases NCoD. Opportunities and challenges in diestive diseases research: Recommendations  
of the National Commission on Digestive Diseases - Diseases of the oropharynx and esophagus. 
Volume 2009.  
18. Sgouros SN, Bergele C, Mantides A. Eosinophilic esophagitis in adults: a systematic review. Eur J 
Gastroenterol Hepatol 2006;18:211 -7. 
19. Dellon  ES, Aderoju A, Woosley JT, Sandler RS, Shaheen NJ. Variability in diagnostic criteria for 
eosinophilic esophagitis: A systematic review. Am J Gastro 2007;102:2300 -13. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 19 
Version: March 14, 2019  
CONFIDENTIAL  20. Kapel RC, Miller JK, Torres C, Aksoy S, Lash R, Katzka DA. Eosinophilic esophagitis:  a prevalent 
disease in the United States that affects all age groups. Gastroenterology 2008;134:1316 -21. 
21. Dellon ES, Aderoju A, Woosley JT, Sandler RS, Shaheen NJ. Variability in diagnostic criteria for 
eosinophilic esophagitis: A systematic review. Am  J Gastroenterol 2007;102:2300 -13. 
22. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary 
eosinophilic esophagitis: a follow -up of 30 adult patients for up to 11.5 years. Gastroenterology 
2003;125:1660 -9. 
23. Kim HP, Vance RB, Shaheen NJ, Dellon ES. The Prevalence and Diagnostic Utility of Endoscopic 
Features of Eosinophilic Esophagitis: A Meta -Analysis. Clin Gastroenterol Hepatol 2012;10:988 -
996.e5.  
24. Rothenberg ME. Biology and treatment of eosinophilic esopha gitis. Gastroenterology 
2009;137:1238 -49. 
25. Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 
2012;10:1066 -78. 
26. Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, 
Collins MH, Assa'ad AH, Aceves SS, Putnam PE, Rothenberg ME. A randomized, double -blind, 
placebo -controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. 
Gastroenterology 2006;131:1381 -91. 
27. Alexander JA, Jung KW, Arora AS, Enders F, Ka tzka DA, Kephardt GM, Kita H, Kryzer LA, Romero 
Y, Smyrk TC, Talley NJ. Swallowed Fluticasone Improves Histologic but Not Symptomatic 
Responses of Adults with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2012;10:742 -9.e1.  
28. Aceves SS, Bastian JF,  Newbury RO, Dohil R. Oral Viscous Budesonide: A Potential New Therapy 
for Eosinophilic Esophagitis in Children. Am J Gastroenterol 2007;102:2271 -9. 
29. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral Viscous Budesonide Is Effective in Children 
With E osinophilic Esophagitis in a Randomized, Placebo -controlled Trial. Gastroenterology 
2010;139:418 -29. 
30. Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, Bussmann C, Beglinger C, 
Schoepfer A, Simon HU. Budesonide is effective in adolescent and a dult patients with active 
eosinophilic esophagitis. Gastroenterology 2010;139:1526 -37, 1537 e1.  
31. Faubion WA, Jr., Perrault J, Burgart LJ, Zein NN, Clawson M, Freese DK. Treatment of eosinophilic 
esophagitis with inhaled corticosteroids. J Pediatr Gastro enterol Nutr 1998;27:90 -3. 
32. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, Badizadegan K, Furuta GT. 
Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone 
propionate. Gastroenterology 2002;122:1 216-25. 
33. Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic 
esophagitis in adults. Mayo Clin Proc 2003;78:830 -5. 
34. Noel RJ, Putnam PE, Collins MH, Assa'ad AH, Guajardo JR, Jameson SC, Rothenberg ME. Clini cal 
and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin 
Gastroenterol Hepatol 2004;2:568 -75. 
35. Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, 
Brown -Whitehorn T, Mamula P, Mar kowitz JE. Eosinophilic esophagitis: a 10 -year experience in 
381 children. Clin Gastroenterol Hepatol 2005;3:1198 -206. 
36. Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, 
endoscopic, histologic findings, and respon se to treatment with fluticasone propionate. Gastrointest 
Endosc 2006;63:3 -12. 
37. Lucendo AJ, Pascual -Turrion JM, Navarro M, Comas C, Castillo P, Letran A, Caballero MT, Larrauri 
J. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid 
therapy: a case series. Endoscopy 2007;39:765 -71. 
38. Alexander JA, Jung KW, Arora AS, Enders FT, Francis DL, Kita H, Romero Y, Katzka DA, Smyrk 
TC, Talley NJ. A randomized placebo -controlled trial of swallowed fluticasone as treat ment for 
eosinophilic esophagitis. Am J Gastroenterol 2010;105 (Suppl 1):S21 (Ab 58).  
39. Gupta SK, Collins MH, Lewis JD, Farber RH. Efficacy and Safety of Oral Budesonide Suspension 
(OBS) in Pediatric Subjects With Eosinophilic Esophagitis (EoE): Results From the Double -Blind, 
Placebo -Controlled PEER Study Gastroenterology 2011;140 (Suppl 1):S179.  
40. Peery AF, Shaheen NJ, Dellon ES. Practice patterns for the evaluation and treatment of 
eosinophilic oesophagitis. Aliment Pharmacol Ther 2010;32:1373 -82. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 20 
Version: March 14, 2019  
CONFIDENTIAL  41. Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC. Comparison of esomeprazole 
to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55:1313 -9. 
42. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM,  Ivanovic M, Chau A, Woosley 
JT, Madanick RD, Orlando RC, Shaheen NJ. Viscous Topical is More Effective than Nebulized 
Steroid Therapy for Patients with Eosinophilic Esophagitis. Gastroenterology 2012;143:321 -
324.e1.  
43. Dellon ES, Kim HP, Sperry SLW, Rybn icek DA, Woosley JT, Shaheen NJ. Eosinophilic esophagitis 
is a progressive fibrostenotic disease:  Insights from a phenotypic analysis. Gastroenterology 
2013;144 (Suppl 1):S485 -6 (Su1833).  
44. Helou EF, Simonson J, Arora AS. 3 -Yr-Follow -Up of Topical Corti costeroid Treatment for 
Eosinophilic Esophagitis in Adults. Am J Gastroenterol 2008;103:2194 -9. 
45. Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C, Schoepfer A, Simon HU. 
Long -term budesonide maintenance treatment is partially effective for  patients with eosinophilic 
esophagitis. Clin Gastroenterol Hepatol 2011;9:400 -9 e1.  
46. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras C, Katzka DA. ACG Clinical Guideline:  
Evidence based approach to the diagnosis and management of esophageal eos inophilia and 
eosinophilic esophagitis. Am J Gastroenterol 2013, In press.  Epub April 9, 2013.  
47. Winter HS, Madara JL, Stafford RJ, Grand RJ, Quinlan JE, Goldman H. Intraepithelial eosinophils: 
a new diagnostic criterion for reflux esophagitis. Gastroen terology 1982;83:818 -23. 
48. Ruchelli E, Wenner W, Voytek T, Brown K, Liacouras C. Severity of esophageal eosinophilia 
predicts response to conventional gastroesophageal reflux therapy. Pediatr Dev Pathol 1999;2:15 -
8. 
49. Blanchard C, Wang N, Rothenberg ME . Eosinophilic esophagitis: pathogenesis, genetics, and 
therapy. J Allergy Clin Immunol 2006;118:1054 -9. 
50. Hogan SP, Mishra A, Brandt EB, Royalty MP, Pope SM, Zimmermann N, Foster PS, Rothenberg 
ME. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal 
inflammation. Nat Immunol 2001;2:353 -60. 
51. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and 
eosinophils in experimental esophagitis. J Clin Invest 2001;107:83 -90. 
52. Mishra A, Rothenbe rg ME. Intratracheal IL -13 induces eosinophilic esophagitis by an IL -5, eotaxin -
1, and STAT6 -dependent mechanism. Gastroenterology 2003;125:1419 -27. 
53. Blanchard C, Mishra A, Saito -Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human 
interleukin -13-induced respiratory and oesophageal inflammation by anti -human -interleukin -13 
antibody (CAT -354). Clin Exp Allergy 2005;35:1096 -103. 
54. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is 
associated with a T(H)2 -type allergic inflammatory response. J Allergy Clin Immunol 2001;108:954 -
61. 
55. Straumann A, Kristl J, Conus S, Vassina E, Spichtin HP, Beglinger C, Simon HU. Cytokine 
expression in healthy and inflamed mucosa: probing the role of eosinophils in the dige stive tract. 
Inflamm Bowel Dis 2005;11:720 -6. 
56. Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H. Cytokine expression in normal and inflamed 
esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr 
Gastroenterol Nutr 2006;42:22 -6. 
57. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, 
Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, 
Rothenberg ME. Eotaxin -3 and a uniquely conserved gene -expression profile in eosinophilic 
esophagitis. J Clin Invest 2006;116:536 -47. 
58. Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE, Putnam PE, Rothenberg 
ME. Potential of blood eosinophils, eosinophil -derived neurotoxin, and eotaxin -3 as biomarkers of 
eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1328 -36. 
59. Bhattacharya B, Carlsten J, Sabo E, Kethu S, Meitner P, Tavares R, Jakate S, Mangray S, Aswad 
B, Resnick MB. Increased expression of eotaxin -3 distinguishes between eo sinophilic esophagitis 
and gastroesophageal reflux disease. Hum Pathol 2007;38:1744 -1753.  
60. Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, 
Rothenberg ME. IL -13 involvement in eosinophilic esophagitis: transc riptome analysis and 
reversibility with glucocorticoids. J Allergy Clin Immunol 2007;120:1292 -300. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 21 
Version: March 14, 2019  
CONFIDENTIAL  61. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147 -74. 
62. Dellon ES, Chen X, Miller CR, Woosley JT, Shaheen NJ. Diagnostic utility of  major basic protein, 
eotaxin -3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol 
2012;107:1503 -11. 
63. Mueller S, Aigner T, Neureiter D, Stolte M. Eosinophil infiltration and degranulation in oesophageal 
mucosa from adult pa tients with eosinophilic oesophagitis: a retrospective and comparative study 
on pathological biopsy. J Clin Pathol 2006;59:1175 -80. 
64. Abonia JP, Rothenberg ME. Eosinophilic Esophagitis: Rapidly Advancing Insights. Annu Rev Med 
2012;63:421 -34. 
65. Kirsch R, Bokhary R, Marcon MA, Cutz E. Activated mucosal mast cells differentiate eosinophilic 
(allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 
2007;44:20 -6. 
66. Lucendo AJ, Navarro M, Comas C, Pascual JM, Burgos E, Santa maria L, Larrauri J. 
Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in 
eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease 
and the immunologic capacity of the es ophagus. Am J Surg Pathol 2007;31:598 -606. 
67. Mueller S, Neureiter D, Aigner T, Stolte M. Comparison of histological parameters for the diagnosis 
of eosinophilic oesophagitis versus gastro -oesophageal reflux disease on oesophageal biopsy 
material. Histopa thology 2008;53:676 -84. 
68. Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME. 
Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010;126:140 -9. 
69. Dellon ES, Chen X, Miller CR, Fritch ie KJ, Rubinas TC, Woosley JT, Shaheen NJ. Tryptase staining 
of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. Am 
J Gastroenterol 2011;106:264 -71. 
70. Gupta SK. Noninvasive markers of eosinophilic esophagitis. G astrointest Endosc Clin N Am 
2008;18:157 -67; xi.  
71. Protheroe C, Woodruff SA, de Petris G, Mukkada V, Ochkur SI, Janarthanan S, Lewis JC, Pasha 
S, Lunsford T, Harris L, Sharma VK, McGarry MP, Lee NA, Furuta GT, Lee JJ. A novel histologic 
scoring system to  evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin 
Gastroenterol Hepatol 2009;7:749 -755 e11.  
72. Dellon ES, Jones PD, Martin NB, Kelly M, Kim SC, Freeman KL, Dellon EP, Ferris ME, Shaheen 
NJ. Health care transition from pediatric to adult -focused gastroenterology in patients with 
eosinophilic esophagitis. Dis Esophagus 2013;26.  
73. Dellon ES, Erichsen R, Pedersen L, Shaheen NJ, Baron JA, Sorensen HT, Vyberg M. Development 
and validation of a registry -based definition of eosinophili c esophagitis in Denmark. World J 
Gastroenterol 2013;19:503 -10. 
74. Sperry SLW, Woosley JT, Shaheen NJ, Dellon ES. Influence of race and gender on the 
presentation of eosinophilic esophagitis. Am J Gastroenterol 2012;107:215 -21. 
75. Hurrell JM, Genta RM, D ellon ES. Prevalence of esophageal eosinophilia varies by climate zone 
in the United States. Am J Gastroenterol 2012;107:698 -706. 
76. Dellon ES, Bower JJ, Keku TO, Chen X, Miller CR, Woosley JT, Orlando RC, Shaheen NJ. Markers 
of tyrosine kinase activity i n eosinophilic esophagitis: a pilot study of the FIP1L1 -PDGFRalpha 
fusion gene, pERK 1/2, and pSTAT5. Dis Esophagus 2012;25:166 -74. 
77. Sperry SL, Shaheen NJ, Dellon ES. Toward uniformity in the diagnosis of eosinophilic esophagitis 
(EoE): the effect of gu idelines on variability of diagnostic criteria for EoE. Am J Gastroenterol 
2011;106:824 -32; quiz 833.  
78. Peery AF, Cao H, Dominik R, Shaheen NJ, Dellon ES. Variable reliability of endoscopic findings 
with white -light and narrow -band imaging for patients w ith suspected eosinophilic esophagitis. Clin 
Gastroenterol Hepatol 2011;9:475 -80. 
79. Madanick RD, Shaheen NJ, Dellon ES. A novel balloon pull -through technique for esophageal 
dilation in eosinophilic esophagitis (with video). Gastrointest Endosc 2011;73:1 38-42. 
80. Dellon ES, Peery AF, Shaheen NJ, Morgan DR, Hurrell JM, Lash RH, Genta RM. Inverse 
association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US 
pathology database. Gastroenterology 2011;141:1586 -92. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 22 
Version: March 14, 2019  
CONFIDENTIAL  81. Dellon ES, Gi bbs WB, Rubinas TC, Fritchie KJ, Madanick RD, Woosley JT, Shaheen NJ. 
Esophageal dilation in eosinophilic esophagitis: Safety and predictors of clinical response and 
complications. Gastrointest Endosc 2010;71:706 -12. 
82. Dellon ES, Fritchie KJ, Rubinas TC,  Woosley JT, Shaheen NJ. Inter - and intraobserver reliability 
and validation of a new method for determination of eosinophil counts in patients with esophageal 
eosinophilia. Dig Dis Sci 2010;55:1940 -9. 
83. Dellon ES, Speck O, Woodward K, Woosley JT, Shahee n NJ. The patchy nature of esophageal 
eosinophilia in eosinophilic esophagitis: Insights from pathology samples from a clinical trial. 
Gastroenterology 2012;142 (Suppl 2):Ab Su1129.  
84. Terry NG, Zhu Y, Rinehart MT, Brown WJ, Gebhart SC, Bright S, Carretta  E, Ziefle CG, Panjehpour 
M, Galanko J, Madanick RD, Dellon ES, Trembath D, Bennett A, Goldblum JR, Overholt BF, 
Woosley JT, Shaheen NJ, Wax A. Detection of dysplasia in Barrett's esophagus with in vivo depth -
resolved nuclear morphology measurements. Gastr oenterology 2011;140:42 -50. 
85. Zhu Y, Terry NG, Woosley JT, Shaheen NJ, Wax A. Design and validation of an angle -resolved 
low-coherence interferometry fiber probe for in vivo clinical measurements of depth -resolved 
nuclear morphology. J Biomed Opt 2011;16 :011003.  
86. Dellon ES, Velayudham A, Clarke BW, Isaacs KL, Gangarosa LM, Galanko JA, Grimm IS. A 
randomized, controlled, double -blind trial of air insufflation versus carbon dioxide insufflation during 
ERCP. Gastrointest Endosc 2010;72:68 -77. 
87. Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, Dellon ES, Galanko 
JA, Sharpless G, Morgan DR, Spacek MB, Heidt -Davis P, Henke D. Randomised clinical trial: high -
dose acid suppression for chronic cough - a double -blind, placebo -controlled stu dy. Aliment 
Pharmacol Ther 2011;33:225 -34. 
88. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen 
GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, 
Gordon SR, Edmundowicz SA, M adanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, 
Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, 
Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in 
Barrett's eso phagus with dysplasia. Gastroenterology 2011;141:460 -8. 
89. Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D. Clinical trials: healing 
of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual 
delayed -release formulation --results from two randomized controlled studies. Aliment Pharmacol 
Ther 2009;29:731 -41. 
90. Shaheen NJ, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S, Russo MW, Galanko J, 
Shrestha R. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a 
randomized, controlled trial. Hepatology 2005;41:588 -94. 
91. Shaheen NJ, Robertson DJ, Crosby MA, Furs SJ, May DT, Harlan WR, Grimm IS, Isaacs KL, 
Bozymski EM. Hyoscyamine as a pharmacological adjunct in colonoscopy: a randomized, double 
blinded, placebo -controlled trial. Am J Gastroenterol 1999;94:2905 -8. 
92. Bischoff -Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA. Effect of calcium 
supplementation on fracture risk: a double -blind randomized controlled trial. Am J Clin Nutr 
2008;87:1945 -51. 
93. MacKenzie T, Comi R, Sluss P, Keisari R, Manwar S, Kim J, Larson R, Baron JA. Metabolic and 
hormonal effects of caffeine: randomized, double -blind, placebo -controlled crossover trial. 
Metabolism 2007;56:1694 -8. 
94. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown -Eyssen G, 
Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, 
Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F , Ueland 
PM, Greenberg ER. Folic acid for the prevention of colorectal adenomas: a randomized clinical 
trial. JAMA 2007;297:2351 -9. 
95. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, 
Horgan K, Loftus S, Morton DG. A randomized trial of rofecoxib for the chemoprevention of 
colorectal adenomas. Gastroenterology 2006;131:1674 -82. 
96. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton 
D, Lanas A, Konstam MA, Baron JA. Cardiov ascular events associated with rofecoxib in a 
colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092 -102. 
Budesonide vs Fluticasone Protocol – TREET Trial   Page 23 
Version: March 14, 2019  
CONFIDENTIAL  97. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown -Eyssen G, Summers 
RW, Rothstein R, Burke CA, Snover DC, Churc h TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers 
T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized 
trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891 -9. 
98. Dellon ES, Speck O, Woodward K , Hores J, Madanick RD, Levinson S, Williams CG, Fritchie KJ, 
Woosley JT, Shaheen NJ. Prospective determination of the prevalence of PPI -responsive 
esophageal eosinophilia in patients with dysphagia undergoing upper endoscopy. Am J 
Gastroenterol 2012;107 ( Suppl 1):S9 (AB 20).  
99. Dellon ES, Lewis JD, Irani AM, ., Hill MR, Hirano I. Development and field testing of a novel patient 
reported outcome measure of dysphagia in patients with eosinophilic esophagitis:  The Dysphagia 
Symptom Questionnaire. Gastroente rology 2013, abstract in press (DDW); paper submitted.  
100. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting 
parallel group randomized trials. Ann Intern Med 2010;152:726 -32. 
101. Schaefer ET, Fitzgerald JF, Molleston  JP, Croffie JM, Pfefferkorn MD, Corkins MR, Lim JD, Steiner 
SJ, Gupta SK. Comparison of oral prednisone and topical fluticasone in the treatment of 
eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165 -73. 
102. Gonsalves N, Policarpio -Nicolas M, Zhang Q, Rao MS, Hirano I. Histopathologic variability and 
endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313 -9. 
103. Hirano I. Therapeutic End Points in Eosinophilic Esophagitis:  Is Elimination of Esophageal 
Eosinophils Enough? Clin Gastroenterol Hepatol 2012;10:750 -2. 
104. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of 
the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and 
grading system. Gut 2013;62:489 -95. 
105. Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RK. Randomized 
controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal 
eosinophilia. Am J Gastroenterol 2013;108:366 -72. 
 
 
 
 